

Central America Region Country Operational Plan FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Summary of Flamme	Summary of Flamiled Funding by Agency and Funding Source						
	Funding Source					Total All	
						Funding	
Aganay				Funding	Applied	Sources and	
Agency	GAP	GHP-State	GHP-USAID	Source Total	Pipeline	Applied	
						Pipeline	
						Amount	
State		258,616		258,616	0	258,616	
USAID		5,425,428	8,391,000	13,816,428	350,615	14,167,043	
DOD		0		0	247,050	247,050	
PC		0		0	43,160	43,160	
HHS/CDC	622,500	6,275,631		6,898,131	0	6,898,131	
Total	622,500	11,959,675	8,391,000	20,973,175	640,825	21,614,000	

Summary of Planned Funding by Budget Code and Agency

			Agency			On Hold	
Budget Code	State	DOD	HHS/CDC	PC	USAID	Amount	Total
НВНС		0	642,394		3,518,628	0	4,161,022
HLAB		0	635,777		0	0	635,777
HTXS			804,529		3,527,603	0	4,332,132
HVCT		0	932,583		573,664	0	1,506,247
HVMS	113,320	0	906,286	0	653,808	0	1,673,414
HVOP		0	1,687,922		3,768,653	0	5,456,575
HVSI	4,200	0	528,281		737,616	0	1,270,097
HVTB			760,359			0	760,359
OHSS	5,880	0			1,036,456	0	1,042,336
	123,400	0	6,898,131	0	13,816,428	0	20,837,959



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
НВНС	4,063,723	0
HVTB	646,865	0
Total Technical Area Planned Funding:	4,710,588	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	541,366	0
HVSI	1,108,120	0
OHSS	962,208	0
Total Technical Area Planned	2 644 604	
Funding:	2,611,694	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HVCT	1,338,287	0
HVOP	5,295,206	0
Total Technical Area Planned Funding:	6,633,493	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	4,199,554	0
Total Technical Area Planned Funding:	4,199,554	0





Technical Area Summary Indicators and Targets

Belize - Central America

(No data provided.)



Technical Area Summary Indicators and Targets

Costa Rica

(No data provided.)



Technical Area Summary Indicators and Targets

El Salvador

Indicator Number	Label	2017
	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,521
	Total estimated number of key population in the catchment area	10,918
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	5,589



the minimum standards required)	
By key population type: Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are based on evidence and/or meet the	
minimum standards required)	
By key population type: Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	0
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	022
level HIV preventive interventions	932
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	



populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	8,518
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	2,400
Total estimated number of key	



	population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV	
KP_PREV_TA	preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group	3,629



level HIV preventive interventions	
that are based on evidence and/or	
meet the minimum standards	
required	
Total estimated number of key	4,352
population in the catchment area	4,552
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	540
level HIV preventive interventions	519
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Female	
sex workers (FSW) (Denominator:	4 755
Total estimated number of key	1,755
population in the catchment area)	
By key population type: Males who	
inject drugs (Male PWID)	
, , ,	



(Denominator: Total estimated number of key population in the catchment area)	
By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,502
By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with	608



individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men and are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Men who	
have sex with men and are NOT	
sex workers (Denominator: Total	2,234
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	363
estimated number of key	
population in the catchment area)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Denominator: Total estimated	
number of key population in the	



	catchment area)		
	By Service: KP known positive		
	By Service: KP was tested as part		
	of the program and/or KP was		
	referred for testing as part of the		
	program		
	By New Client Status: New		
	beneficiary		
	By New Client Status: Returning		
	beneficiary within the current report		
	period		
	Number of individuals who received		
	T&C services for HIV and received	3,580	
	their test results during the past 12 months		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
HTC_TST_DSD	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Test Result by Age and Sex:		
	Positive: 10-14 Male		
	Test Result by Age and Sex:		
	Positive: 15-19 Male		
	Test Result by Age and Sex:		
	Positive: 20-24 Male		



Test Result by Age and Sex:	
Positive: 25-49 Male	
Test Result by Age and Sex:	
Positive: 50+ Male	
Test Result by Age and Sex:	
Positive: 10-14 Female	
Test Result by Age and Sex:	
Positive: 15-19 Female	
Test Result by Age and Sex:	
Positive: 20-24 Female	
Test Result by Age and Sex:	
Positive: 25-49 Female	
Test Result by Age and Sex:	
Positive: 50+ Female	
Test Result by Age and Sex:	
Negative: 10-14 Male	
Test Result by Age and Sex:	
Negative: 15-19 Male	
Test Result by Age and Sex:	
Negative: 20-24 Male	
Test Result by Age and Sex:	
Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	



_		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH	3,054
H	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
H	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	526
	Fest Result by Aggregated Age and Sex: Negative <15 Male	
	Fest Result by Aggregated Age and Sex: Negative 15+ Male	
	Fest Result by Aggregated Age and Sex: Negative <15 Female	
	Fest Result by Aggregated Age and Sex: Negative 15+ Female	
	Fest Result by Aggregated Age and Sex: Positive <15 Male	
	Fest Result by Aggregated Age and Sex: Positive 15+ Male	164
	Fest Result by Aggregated Age and Sex: Positive <15 Female	
	Fest Result by Aggregated Age and Sex: Positive 15+ Female	21
1	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
ļ	Age/sex: <1	
ļ	Age/sex: 1-9	
5	Service Delivery Point	
(Community): Index testing	
	Service Delivery Point	
(Community): Homebased testing	



Service Delivery Point	2 260
(Community): Mobile testing	3,260
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	
Other PITC	
Service Delivery Point (Facility):	
VCT	
Service Delivery Point (Facility):	
VMMC	



Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by Age: <15 VMMC	
Service Delivery Point (Facility) by Age: >15 VMMC	



e Delivery Point (Facility) by 15 PMTCT
Delivery Point (Facility) by
Delivery Point (Facility) by 15 TB Clinics
Delivery Point (Facility) by 15 TB Clinics
Delivery Point (Facility) by 15 Index testing
Delivery Point (Facility) by 15 Index testing
er of individuals who received ervices for HIV and received st results during the past 12
x: 5-9 Male
x: 10-14 Male
x: 15-19 Male
x: 20-24 Male
x: 25-49 Male
x: 50+ Male
x: 5-9 Female
x: 10-14 Female
x: 15-19 Female
x: 20-24 Female
x: 25-49 Female
x: 50+ Female
esult by Age and Sex:
e: 10-14 Male
esult by Age and Sex: e: 15-19 Male
esult by Age and Sex:



Positive: 20-24 Male	
1 CONTIVO. 20 2 1 IVIGIO	
Test Result by Age and Sex:	
Positive: 25-49 Male	
Test Result by Age and Sex:	
Positive: 50+ Male	
Test Result by Age and Sex:	
Positive: 10-14 Female	
Test Result by Age and Sex:	
Positive: 15-19 Female	
Test Result by Age and Sex:	
Positive: 20-24 Female	
Test Result by Age and Sex:	
Positive: 25-49 Female	
Test Result by Age and Sex:	
Positive: 50+ Female	
Test Result by Age and Sex:	
Negative: 10-14 Male	
Test Result by Age and Sex:	
Negative: 15-19 Male	
Test Result by Age and Sex:	
Test Result by Age and Sex: Negative: 20-24 Male	
Negative: 20-24 Male Test Result by Age and Sex:	
Negative: 20-24 Male	
Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex:	
Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male	
Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex: Negative: 50+ Male Test Result by Age and Sex:	
Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex: Negative: 50+ Male	
Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex: Negative: 50+ Male Test Result by Age and Sex: Negative: <1 Female Test Result by Age and Sex:	
Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex: Negative: 50+ Male Test Result by Age and Sex: Negative: <1 Female	
Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex: Negative: 50+ Male Test Result by Age and Sex: Negative: <1 Female Test Result by Age and Sex: Negative: 10-14 Female Test Result by Age and Sex:	
Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex: Negative: 50+ Male Test Result by Age and Sex: Negative: <1 Female Test Result by Age and Sex: Negative: 10-14 Female	
Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex: Negative: 50+ Male Test Result by Age and Sex: Negative: <1 Female Test Result by Age and Sex: Negative: 10-14 Female Test Result by Age and Sex:	
Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex: Negative: 50+ Male Test Result by Age and Sex: Negative: <1 Female Test Result by Age and Sex: Negative: 10-14 Female Test Result by Age and Sex: Negative: 15-19 Female	



	Negative: 25-49 Female	
	Test Result by Age and Sex:	
	Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,863
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	311
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	98
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	14
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point	



(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	
Other PITC	
Service Delivery Point (Facility):	2,117



VCT	
Service Delivery Point (Facility): VMMC	
Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	57
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by	-



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
ΓB_STAT_TA		
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	17
	Total number of registered new and relapsed TB cases, during the reporting period.	20
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



Age/Sex: Male 10-14 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 15-19 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 20-24 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 10-14	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 15-19	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 20-24	



(N	lumerator: Number of registered	
ne	ew and relapsed TB cases with	
do	ocumented HIV status, during the	
re	porting period)	
Αç	ge/Sex: Female 25-49	
(N	lumerator: Number of registered	
ne	ew and relapsed TB cases with	
do	ocumented HIV status, during the	
re	porting period)	
Αç	ge/Sex: Female 50+ (Numerator:	
Νι	umber of registered new and	
re	lapsed TB cases with	
do	ocumented HIV status, during the	
re	porting period)	
Αç	ggregated Age/Sex: Male <15	
(N	lumerator: Number of registered	
ne	ew and relapsed TB cases with	
do	ocumented HIV status, during the	
re	porting period)	
Αç	ggregated Age/Sex: Male 15+	
(N	lumerator: Number of registered	
ne	ew and relapsed TB cases with	12
do	ocumented HIV status, during the	
re	porting period)	
Αç	ggregated Age/Sex: Female <15	
(N	lumerator: Number of registered	
ne	ew and relapsed TB cases with	
do	ocumented HIV status, during the	
re	porting period)	
Αç	ggregated Age/Sex: Female 15+	
(N	lumerator: Number of registered	
ne	ew and relapsed TB cases with	5
do	ocumented HIV status, during the	
re	porting period)	
Re	esult: Known HIV positive at	
se	ervice entry	



Result: New HIV	positive	
Result: HIV nega	ative	
,	nominator: Total	
number of regist relapsed TB cas		
reporting period)	_	
	enominator: Total	
number of regist		
relapsed TB cas		
reporting period)	_	
Age/Sex: Male 1		
(Denominator: T		
registered new a		
cases, during the	e reporting period)	
Age/Sex: Male 1	5-19	
(Denominator: T	otal number of	
registered new a	and relapsed TB	
cases, during the	e reporting period)	
Age/Sex: Male 2	0-24	
(Denominator: T	otal number of	
registered new a	ind relapsed TB	
cases, during the	e reporting period)	
Age/Sex: Male 2	5-49	
(Denominator: T	otal number of	
registered new a	ind relapsed TB	
cases, during the	e reporting period)	
	0+ (Denominator:	
	registered new and	
relapsed TB cas	•	
reporting period)		
Age/Sex: Female		
(Denominator: T		
registered new a	·	
	e reporting period)	
Age/Sex: Female	e 15-19	



	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 20-24	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 25-49	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	TB_ART_TA Percentage of	
	HIV-positive new and relapsed	
	registered TB cases on ART during	n/a
	TB treatment	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	2
	ART during TB treatment during	_
	the reporting period	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status during TB	4
_ART_TA	treatment during the reporting	·
	period	
	Age/Sex: <1 (Numerator: The	
	number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Age/Sex: 1-9 (Numerator: The	
	number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during	
	part daming 12 troutment daming	



the reporting period)	
the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 15-19 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 20-24 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 25-49 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 10-14	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	



ART during TB treatment during
the reporting period)
Age/Sex: Female 15-19
(Numerator: The number of
registered new and relapse TB
cases with documented
HIV-positive status who are on
ART during TB treatment during
the reporting period)
Age/Sex: Female 20-24
(Numerator: The number of
registered new and relapse TB
cases with documented
HIV-positive status who are on
ART during TB treatment during
the reporting period)
Age/Sex: Female 25-49
(Numerator: The number of
registered new and relapse TB
cases with documented
HIV-positive status who are on
ART during TB treatment during
the reporting period)
Age/Sex: Female 50+ (Numerator:
The number of registered new and
relapse TB cases with documented
HIV-positive status who are on
ART during TB treatment during
the reporting period)
Aggregated Age/Sex: Male <15
(Numerator: The number of
registered new and relapse TB
cases with documented
HIV-positive status who are on
ART during TB treatment during
the reporting period)
1 31/



Aggregated Age/Sex: Male 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	1
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	1
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
On ART: Already on ART	
On ART: New on ART	
Age/Sex: <1 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: 1-9 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
 Age/Sex: Male 10-14	



	1
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 25-49	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 50+ (Denominator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 10-14	
(Denominator: The number of	
registered new and relapse TB	



cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 25-49	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 50+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Male <15	
(Denominator: The number of	
`	
registered new and relapse TB cases with documented	



	· · · · · · · · · · · · · · · · · · ·	
	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	Aggregated Age/Sex: Male 15+	
	(Denominator: The number of	
	registered new and relapse TB	
	cases with documented	
	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	Aggregated Age/Sex: Female <15	
	(Denominator: The number of	
	registered new and relapse TB	
	cases with documented	
	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of	
	,	
	registered new and relapse TB	
	cases with documented	
	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	The number of PLHIV who were	
	screened for TB symptoms at the	
	last clinical visit at a HIV facility	
	during the reporting period.	
B_SCREENDX_TA	Screened for TB by Age/Sex: <15	
	Male	
	Screened for TB by Age/Sex: 15+	115
	Male	110
	Screened for TB by Age/Sex: <15	
	Female	
	Screened for TB by Age/Sex: 15+	85



	Female	
	Screen Results: Screened Positive for TB	4
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	2
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	
	TB_SCREEN_TA Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a
B_SCREEN_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	200
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral	
	load Age: <1	



	Age: 1-4	
	Age: 5-9	
	Age: 10-14	
	Age: 15-19	
	Age: 20+	
	Sum of Age disaggregates	
	Aggregated Age - USE WITH HQ	
	PERMISSION ONLY: <15	
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	
	Sum of Aggregated Age disaggregates	
	Sex: Female	
	Sex: Male	
	Sum of Sex disaggregates	
	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	CD4: Number of laboratories that perform this testing	1
	CD4: Number of laboratories that	1



participate in this PT program	
CD4: Number of laboratories that	
achieve acceptable successful	1
passing criteria in this PT program	
Early infant diagnostics: Number of	
laboratories that perform this	
testing	
Early infant diagnostics: Number of	
laboratories that participate in this	
PT program	
Early infant diagnostics: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
HIV viral load: Number of	
laboratories that perform this	1
testing	
HIV viral load: Number of	
laboratories that participate in this	1
PT program	
HIV viral load: Number of	
laboratories that achieve	1
acceptable successful passing	
criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	



	1
	Number of laboratories that
	perform this testing
	TB diagnostics (Xpert MTB/RIF):
	Number of laboratories that
	participate in this PT program
	TB diagnostics (Xpert MTB/RIF):
	Number of laboratories that
	achieve acceptable successful
	passing criteria in this PT program
	TB diagnostics (Culture/DST):
	Number of laboratories that
	perform this testing
	TB diagnostics (Culture/DST):
	Number of laboratories that
	participate in this PT program
	TB diagnostics (Culture/DST):
	Number of laboratories that
	achieve acceptable successful
	passing criteria in this PT program
	Percentage of laboratories and
	POC testing sites that perform HIV
	diagnostic testing that participate
	and successfully pass in an
	analyte-specific proficiency testing
	(PT) program
	CD4: Number of laboratories that
	achieve acceptable successful
LAB_PT_TA	passing criteria in this PT program
	CD4: Number of laboratories that
	participate in this PT program
	CD4: Number of laboratories that
	perform this testing
	Early infant diagnostics: Number of
	laboratories that achieve
	acceptable successful passing
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1



criteria in this PT program	
Early infant diagnostics: Number of	
laboratories that participate in this	
PT program	
Early infant diagnostics: Number of	
laboratories that perform this	
testing	
HIV serologic/diagnostic testing:	
Number of laboratories that	5
achieve acceptable successful	3
passing criteria in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	4
participate in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	4
perform this testing	
HIV viral load: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
HIV viral load: Number of	
laboratories that participate in this	
PT program	
HIV viral load: Number of	
laboratories that perform this	
testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	



Number of laboratories that perform this testing	
TB diagnostics (Xpert MTB/RIF): Number of laboratories that	
achieve acceptable successful passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF): Number of laboratories that	
participate in this PT program TB diagnostics (Xpert MTB/RIF): Number of laboratories that	
perform this testing TB diagnostics (Culture/DST):	
Number of laboratories that achieve acceptable successful passing criteria in this PT program	
TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
TB diagnostics (Culture/DST): Number of laboratories that perform this testing	



Technical Area Summary Indicators and Targets

Guatemala

Indicator Number	Label	2017
	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	19,987
	Total estimated number of key population in the catchment area	25,453
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	19,766



the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	224
individual and/or small group level	221
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	
level HIV preventive interventions	
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	



populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	25,049
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	455
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	
Total estimated number of key	



	population in the catchment area)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: REturniong	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	44 477
	their test results during the past 12	11,477
	months	
HTC_TST_DSD	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	₁ . 130, 00% 20 10 Maio	



Age/sex: 50+ Male	
Age/sex: 5-9 Female	
Age/sex: 10-14 Female	
Age/sex: 15-19 Female	
Age/sex: 20-24 Female	
Age/sex: 25-49 Female	
Age/sex: 50+ Female	
Test Result by Age and Sex:	
Positive: 10-14 Male	
Test Result by Age and Sex:	
Positive: 15-19 Male	
Test Result by Age and Sex:	
Positive: 20-24 Male	
Test Result by Age and Sex:	
Positive: 25-49 Male	
Test Result by Age and Sex:	
Positive: 50+ Male	
Test Result by Age and Sex:	
Positive: 10-14 Female	
Test Result by Age and Sex:	
Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female	
Test Result by Age and Sex: Positive: 25-49 Female	
Test Result by Age and Sex:	
Positive: 50+ Female	
Test Result by Age and Sex:	
Negative: 10-14 Male	
Test Result by Age and Sex:	
Negative: 15-19 Male	
Test Result by Age and Sex:	
Negative: 20-24 Male	
Test Result by Age and Sex:	



Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH	11,357
HQ PERMISSION ONLY: 15+ Male	11,007
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	120
Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	
and Sex: Positive <15 Male	
Test Result by Aggregated Age	575



	and Sex: Positive 15+ Male	
	Test Result by Aggregated Age	
	and Sex: Positive <15 Female	
	Test Result by Aggregated Age	0
	and Sex: Positive 15+ Female	6
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point	
	(Community): Index testing	
	Service Delivery Point	
	(Community): Homebased testing	
	Service Delivery Point	F 744
	(Community): Mobile testing	5,741
	Service Delivery Point	
	(Community): Other	
	Service Delivery Point (Community)	
	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility):	



Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	
Other PITC	
Service Delivery Point (Facility):	4,965
VCT	4,903
Service Delivery Point (Facility):	
VMMC	
Service Delivery Point (Facility):	
PMTCT	
Service Delivery Point (Facility): TB	
Clinics	
Service Delivery Point (Facility):	131
Index testing	101
Service Delivery Point (Facility) by	
Age: <15 Inpatient	
Service Delivery Point (Facility) by	
Age: >15 Inpatient	
Service Delivery Point (Facility) by	
Age: <15 Outpatient	
Service Delivery Point (Facility) by	
Age: >15 Outpatient	
Age: >15 Outpatient	
Age: >15 Outpatient Service Delivery Point (Facility) by	
Age: >15 Outpatient Service Delivery Point (Facility) by Age: <15 Pediatroc	
Age: >15 Outpatient Service Delivery Point (Facility) by Age: <15 Pediatroc Service Delivery Point (Facility) by	
Age: >15 Outpatient Service Delivery Point (Facility) by Age: <15 Pediatroc Service Delivery Point (Facility) by Age: >15 Pediatroc	



	1	
	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	TB_STAT_TA Percentage of	
	registered new and relapsed TB	
	cases with documented HIV status.	n/a
TB_STAT_TA		
	Number of registered new and	
	relapsed TB cases with	468
	documented HIV status, during the	.50
	reporting period.	



Total number of registered new and	
relapsed TB cases, during the	566
reporting period.	
Age/Sex: <1 (Numerator: Number	
of registered new and relapsed TB	
cases with documented HIV status,	
during the reporting period)	
Age/Sex: 1-9 (Numerator: Number	
of registered new and relapsed TB	
cases with documented HIV status,	
during the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 15-19 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 20-24 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	



Age/Sex: Female 10-14	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 15-19	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 20-24	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 25-49	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: Number of registered	
new and relapsed TB cases with	5
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	322
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female <15	
100 0 0	



(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	141
documented HIV status, during the	
reporting period)	
Result: Known HIV positive at	
service entry	
Result: New HIV positive	
Result: HIV negative	
Age/Sex: <1 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: 1-9 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: Male 10-14	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 15-19	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 20-24	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 25-49	
(Denominator: Total number of	



	1	ı
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator:	
	Total number of registered new and	
	relapsed TB cases, during the	
	reporting period)	
	Age/Sex: Female 10-14	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 15-19	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 20-24	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 25-49	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	TB_ART_TA Percentage of	
	HIV-positive new and relapsed	
	registered TB cases on ART during	n/a
	TB treatment	
	The number of registered new and	
	relapse TB cases with documented	
TB_ART_TA	HIV-positive status who are on	9
	ART during TB treatment during	j
	the reporting period	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status during TB	25
	treatment during the reporting	
	meannerit during the reporting	



period	
Age/Sex: <1 (Numerator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: 1-9 (Numerator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 15-19 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 20-24 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 25-49 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	



the reporting period)	
Age/Sex: Male 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 10-14	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 15-19	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 20-24	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 25-49	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 50+ (Numerator:	



The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	6
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	3
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
On ART: Already on ART	
On ART: New on ART	
Age/Sex: <1 (Denominator: The	-



number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: 1-9 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 25-49	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	



i T	\neg
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 50+ (Denominator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 25-49	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
1	



period)	
Age/Sex: Female 50+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Male <15	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Male 15+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Female <15	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Female 15+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	



	The number of PLHIV who were	
	screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	
	Screened for TB by Age/Sex: <15 Male	
	Screened for TB by Age/Sex: 15+ Male	660
	Screened for TB by Age/Sex: <15 Female	
	Screened for TB by Age/Sex: 15+ Female	285
	Screen Results: Screened Positive for TB	19
TD CODEENDY TA	TB Positive by Age/Sex: <15 Male	
TB_SCREENDX_TA	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15	
	Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	11
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	11
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	8
TB_SCREEN_TA	TB_SCREEN_TA Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the	n/a



	reporting period.	
	The number of PLHIV who were	
	screened for TB symptoms at the	945
	last clinical visit to an HIV care	945
	facility during the reporting period	
	Number of HIV positive adults and	
	children who received at least one	
	of the following during the reporting	
	period: clinical assessment (WHO	
	staging) OR CD4 count OR viral	
	load	
	Age: <1	
	Age: 1-4	
	Age: 5-9	
	Age: 10-14	
	Age: 15-19	
	Age: 20+	
	Sum of Age disaggregates	
	Aggregated Age - USE WITH HQ	
	PERMISSION ONLY: <15	
	Aggregated Age - USE WITH HQ	
	PERMISSION ONLY: 15+	
	Sum of Aggregated Age	
	disaggregates	
	Sex: Female	
	Sex: Male	
	Sum of Sex disaggregates	
	Number of adults and children	
	receiving antiretroviral therapy	10,174
	(ART)	
TX_CURR_TA	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	



Age/Sex: 20+ Male Age/Sex: <1 Female Age/Sex: <1-4 Female Age/Sex: 15-19 Female Age/Sex: 15-19 Female Age/Sex: 20+ Female Age/Sex: 20+ Female Age/Sex: 20+ Female Sum of Age/Sex disaggregations Aggregated Age/Sex: <1 Male Aggregated Age/Sex: <1 Female Aggregated Age/Sex: <15 Male Aggregated Age/Sex: <15 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15- Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex 10-14 Female Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 20-24 Male Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 20-24 Female			
Age/Sex: 1-4 Female Age/Sex: 5-14 Female Age/Sex: 5-14 Female Age/Sex: 20+ Female Sum of Age/Sex disaggregations Aggregated Age/Sex: <1 Male Aggregated Age/Sex: <1 Female Aggregated Age/Sex: <1 Female Aggregated Age/Sex: <15 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Sum of Aggregated Age/Sex: 15+ Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex disaggregates 10,174 Age/Sex: -10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 20-24 Male Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 20-49 Female Age/Sex: 50+ Female		Age/Sex: 20+ Male	
Age/Sex: 5-14 Female Age/Sex: 15-19 Female Age/Sex: 20+ Female Sum of Age/Sex disaggregations Aggregated Age/Sex: <1 Male Aggregated Age/Sex: <1 Female Aggregated Age/Sex: <15 Male Aggregated Age/Sex: <15 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: 15 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15 Sum of Aggregated Age/Sex 415 Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex disaggregates Age/Sex: <1 Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female		Age/Sex: <1 Female	
Age/Sex: 15-19 Female Age/Sex: 20+ Female Sum of Age/Sex disaggregations Aggregated Age/Sex: <1 Male Aggregated Age/Sex: <1 Female Aggregated Age/Sex: <15 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: <15 Female Aggregated Age/Sex: <15 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 1-15 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Sum of Aggregated Age/Sex <15 Sum of Aggregated Age/Sex disaggregates Age/Sex: 1-9 Age/Sex: 1-9 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 20-24 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female		Age/Sex: 1-4 Female	
Age/Sex: 20+ Female Sum of Age/Sex disaggregations Aggregated Age/Sex: <1 Male Aggregated Age/Sex: <15 Male Aggregated Age/Sex: <15 Male Aggregated Age/Sex: <15 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: <15 Female Aggregated Age/Sex: <15 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 1-15 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15 Sum of Aggregated Age/Sex 15 Sum of Aggregated Age/Sex (15 Sum of Aggregated Age/Sex (15 Sum of Aggregated Age/Sex: 10-174 Sum of Aggregated Age/Sex disaggregates Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female		Age/Sex: 5-14 Female	
Sum of Age/Sex disaggregations Aggregated Age/Sex: <1 Male Aggregated Age/Sex: <15 Male Aggregated Age/Sex: <15 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 11-14 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Sum of Aggregated Age/Sex <15 Sum of Aggregated Age/Sex disaggregates Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 20-24 Male Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 20-54 Female Age/Sex: 50+ Female		Age/Sex: 15-19 Female	
Aggregated Age/Sex: <1 Male Aggregated Age/Sex: <1 Female Aggregated Age/Sex: <15 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex <15 Sum of Aggregated Age/Sex <15 Sum of Aggregated Age/Sex disaggregates Age/Sex: -1 Age/Sex: -1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 20-24 Male Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 20-49 Female Age/Sex: 50+ Female Age/Sex: 50+ Female		Age/Sex: 20+ Female	
Aggregated Age/Sex: <1 Female Aggregated Age/Sex: <15 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: <15 Female Aggregated Age/Sex: <15 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex <15 Sum of Aggregated Age/Sex <15 Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex 10,174 Sum of Aggregated Age/Sex disaggregates Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Sum of Age/Sex disaggregations	
Aggregated Age/Sex: <15 Male Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: <15 Female Aggregated Age/Sex: <15 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15 Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex disaggregated Age/Sex disaggregated Age/Sex disaggregates 10,174 Age/Sex: <1 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female		Aggregated Age/Sex: <1 Male	
Aggregated Age/Sex: 1-14 Male Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: <15 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15 Sum of Aggregated Age/Sex <15 Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex disaggregates 10,174 Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female		Aggregated Age/Sex: <1 Female	
Aggregated Age/Sex: 15+ Male Aggregated Age/Sex: <15 Female Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex <15 Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex disaggregates 10,174 Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 20-24 Male Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Aggregated Age/Sex: <15 Male	
Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex: 15+ Female 4,357 Sum of Aggregated Age/Sex <15 Sum of Aggregated Age/Sex 15+ 10,174 Sum of Aggregated Age/Sex disaggregates 10,174 Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 20-24 Female Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female		Aggregated Age/Sex: 1-14 Male	
Aggregated Age/Sex: 1-14 Female Aggregated Age/Sex: 15+ Female Aggregated Age/Sex <15 Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex 10,174 Sum of Aggregated Age/Sex disaggregates Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Aggregated Age/Sex: 15+ Male	5,817
Aggregated Age/Sex: 15+ Female Sum of Aggregated Age/Sex <15 Sum of Aggregated Age/Sex 15+ 10,174 Sum of Aggregated Age/Sex disaggregates Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Aggregated Age/Sex: <15 Female	
Sum of Aggregated Age/Sex <15 Sum of Aggregated Age/Sex 15+ 10,174 Sum of Aggregated Age/Sex 10,174 Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Aggregated Age/Sex: 1-14 Female	
Sum of Aggregated Age/Sex 15+ Sum of Aggregated Age/Sex disaggregates Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Aggregated Age/Sex: 15+ Female	4,357
Sum of Aggregated Age/Sex disaggregates Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female		Sum of Aggregated Age/Sex <15	
disaggregates Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Sum of Aggregated Age/Sex 15+	10,174
Age/Sex: <1 Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Sum of Aggregated Age/Sex	40.474
Age/Sex: 1-9 Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female		disaggregates	10,174
Age/Sex: 10-14 Male Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female		Age/Sex: <1	
Age/Sex: 10-14 Female Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female		Age/Sex: 1-9	
Sum of Aggregated Age/Sex (<1 and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 25-49 Female		Age/Sex: 10-14 Male	
and 1-14) <15 Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Age/Sex: 10-14 Female	
Age/Sex: 20-24 Male Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Sum of Aggregated Age/Sex (<1	
Age/Sex: 25-49 Male Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		and 1-14) <15	
Age/Sex: 50+ Male Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Age/Sex: 20-24 Male	
Age/Sex: 20-24 Female Age/Sex: 25-49 Female Age/Sex: 50+ Female		Age/Sex: 25-49 Male	
Age/Sex: 25-49 Female Age/Sex: 50+ Female		Age/Sex: 50+ Male	
Age/Sex: 50+ Female		Age/Sex: 20-24 Female	
		Age/Sex: 25-49 Female	
		Age/Sex: 50+ Female	
TX_NEW_TA Number of adults and children 410	TX_NEW_TA	Number of adults and children	410



newly enrolled on antiretroviral	
therapy (ART)	
By Age/Sex: <1	
By Age/Sex: 1-9	
By Age/Sex: <1 Male	
By Age/Sex: 1-4 Male	
By Age/Sex: 5-9 Male	
By Age/Sex: 10-14 Male	
By Age/Sex: 15-19 Male	
By Age/Sex: 20-24 Male	
By Age/Sex: 25-49 Male	
By Age/Sex: 50+ Male	
By Age/Sex: <1 Female	
By Age/Sex: 1-4 Female	
By Age/Sex: 5-9 Female	
By Age/Sex: 10-14 Female	
By Age/Sex: 15-19 Female	
By Age/Sex: 20-24 Female	
By Age/Sex: 25-49 Female	
By Age/Sex: 50+ Female	
Sum of Age/Sex disaggregates	
Aggregated Grouping by Age: <1	
Aggregated Grouping by Age: <1 Male	
Aggregated Grouping by Age/Sex: <15 Male	0
Aggregated Grouping by Age/Sex: 1-14 Male	
Aggregated Grouping by Age/Sex: 15+ Male	410
Aggregated Grouping by Age: <1 Female	-
Aggregated Grouping by Age/Sex:	0



	<15 Female	
	Aggregated Grouping by Age/Sex:	
	1-14 Female	
	Aggregated Grouping by Age/Sex:	0
	15+ Female	
	Sum of Aggregated Age/Sex	410
	disaggregates	
	Pregnancy status	
	Breastfeeding status	
	Percentage of laboratories and	
	POC testing sites that perform HIV	
	diagnostic testing that participate	
	and successfully pass in an	
	analyte-specific proficiency testing	
	(PT) program	
	HIV serologic/diagnostic testing:	
	Number of laboratories that	9
	perform this testing	
LAB_PT_DSD	HIV serologic/diagnostic testing:	
	Number of laboratories that	6
	participate in this PT program	
	HIV serologic/diagnostic testing:	
	Number of laboratories that	9
	achieve acceptable successful	
	passing criteria in this PT program	
	CD4: Number of laboratories that	5
	perform this testing	
	CD4: Number of laboratories that	5
	participate in this PT program	
	CD4: Number of laboratories that achieve acceptable successful	5
	passing criteria in this PT program	Ü
	Early infant diagnostics: Number of	
	laboratories that perform this testing	
	leating	



Early infant diagnostics: Number of	
laboratories that participate in this	
PT program	
Early infant diagnostics: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
HIV viral load: Number of	
laboratories that perform this	2
testing	
HIV viral load: Number of	
laboratories that participate in this	2
PT program	
HIV viral load: Number of	
laboratories that achieve	0
acceptable successful passing	2
criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	



	achieve acceptable successful
	passing criteria in this PT program
	TB diagnostics (Culture/DST):
	Number of laboratories that
	perform this testing
	TB diagnostics (Culture/DST):
	Number of laboratories that
	participate in this PT program
	TB diagnostics (Culture/DST):
	Number of laboratories that
	achieve acceptable successful
	passing criteria in this PT program
	Percentage of laboratories and
	POC testing sites that perform HIV
	diagnostic testing that participate
	and successfully pass in an
	analyte-specific proficiency testing
	(PT) program
	CD4: Number of laboratories that
	achieve acceptable successful
	passing criteria in this PT program
	CD4: Number of laboratories that
	participate in this PT program
LAB_PT_TA	CD4: Number of laboratories that
	perform this testing
	Early infant diagnostics: Number of
	laboratories that achieve
	acceptable successful passing
	criteria in this PT program
	Early infant diagnostics: Number of
	laboratories that participate in this
	PT program
	Early infant diagnostics: Number of
	laboratories that perform this
	testing
	leaning



HIV serologic/diagnostic testing:	
Number of laboratories that	3
achieve acceptable successful	3
passing criteria in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	3
participate in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	6
perform this testing	
HIV viral load: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
HIV viral load: Number of	
laboratories that participate in this	
PT program	
HIV viral load: Number of	
laboratories that perform this	
testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	



	,
Number of laboratories that participate in this PT program	
TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
TB diagnostics (Culture/DST): Number of laboratories that perform this testing	



Technical Area Summary Indicators and Targets

Honduras

Indicator Number	Label	2017
	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,615
	Total number of people in the target population	
	Age/sex: 10-14 Male	
PP_PREV_DSD	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	



	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14	
	Female	
	Denominator: Age/sex: 15-19	
	Female	
	Denominator: Age/sex: 20-24	
	Female	
	Denominator: Age/sex: 25-49	
	Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for	
	testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
	KP_PREV_DSD Percentage of key	
	populations reached with individual	
	and/or small group level HIV	n/a
	preventive interventions that are	.,.
	based on evidence and/or meet the	
	minimum standards required (DSD)	
KP_PREV_DSD	Number of key populations reached	
	with individual and/or small group level HIV preventive interventions	
	that are based on evidence and/or	5,449
	meet the minimum standards	
	required	
	Total estimated number of key	
	population in the catchment area	16,354
	By key population type: Men who	



have sex with men who are sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Numerator: Number	
of key populations reached with	0.044
individual and/or small group level	3,811
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	1,638
with individual and/or small group	•
level HIV preventive interventions	



that are based on evidence and/or meet the minimum standards required)	
By key population type: Males who	
inject drugs (Male PWID) (Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	
estimated number of key	



•	1
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	225
Total estimated number of key	225
population in the catchment area)	
By key population type: Males who	
inject drugs (Male PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Females	
who inject drugs (Female PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: People in	
prisons and enclosed settings	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By Service: KP known status	
By Service: KP was tested as part	
of the program and/or KP was	
referred for testing as part of the	
program	



	By New Client Status: New		
	beneficiary		
	By New Client Status: REturniong		
	beneficiary within the current report		
	period		
	KP_PREV_TA Percentage of key		
	populations reached with individual		
	and/or small group level HIV		
	preventive interventions that are		
	based on evidence and/or meet the		
	minimum standards required		
	(TA-only)		
	Number of key populations reached		
	with individual and/or small group		
	level HIV preventive interventions		
	that are based on evidence and/or	11,871	
	meet the minimum standards		
	required		
	Total estimated number of key		
	population in the catchment area	17,979	
KP_PREV_TA	By key population type: Female		
	sex workers (FSW) (Numerator:		
	Number of key populations reached		
	with individual and/or small group		
	level HIV preventive interventions	2,323	
	that are based on evidence and/or		
	meet the minimum standards		
	required)		
	By key population type: Males who		
	inject drugs (Male PWID)		
	(Numerator: Number of key		
	populations reached with individual		
	and/or small group level HIV	0	
	preventive interventions that are		
	l.		
	based on evidence and/or meet the		



1		
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individua and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	5,952
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	O
	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that	9,548



L.	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	0
and/or small group level HIV	U
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	0
individual and/or small group level	0
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men and are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Men who	
have sex with men and are NOT	
sex workers (Denominator: Total	12,027
estimated number of key	•
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
workers (Denominator, 10tal	



	estimated number of key	
	population in the catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Numerator: Number of key	
	populations reached with individual	0
	and/or small group level HIV	0
	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: Returning	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	4.440
	their test results during the past 12	4,419
	months	
	Age/sex: 5-9 Male	
HTC_TST_DSD	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	rigo/sex. Jut Male	



Age/sex: 5-9 Female	
Age/sex: 10-14 Female	
Age/sex: 15-19 Female	
Age/sex: 20-24 Female	
Age/sex: 25-49 Female	
Age/sex: 50+ Female	
Test Result by Age and Sex: Positive: 10-14 Male	
Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male	
Test Result by Age and Sex: Positive: 25-49 Male	
Test Result by Age and Sex: Positive: 50+ Male	
Test Result by Age and Sex: Positive: 10-14 Female	
Test Result by Age and Sex: Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female	
Test Result by Age and Sex: Positive: 25-49 Female	
Test Result by Age and Sex: Positive: 50+ Female	
Test Result by Age and Sex: Negative: 10-14 Male	
Test Result by Age and Sex: Negative: 15-19 Male	
Test Result by Age and Sex: Negative: 20-24 Male	
Test Result by Age and Sex: Negative: 25-49 Male	



Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex: Negative: 10-14 Female	
Test Result by Age and Sex: Negative: 15-19 Female	
Test Result by Age and Sex: Negative: 20-24 Female	
Test Result by Age and Sex: Negative: 25-49 Female	
Test Result by Age and Sex: Negative: 50+ Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,154
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,265
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	
Test Result by Aggregated Age and Sex: Positive 15+ Male	152



Test Result by Aggregated Age	
and Sex: Positive <15 Female	
Test Result by Aggregated Age and Sex: Positive 15+ Female	50
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	
(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	0.400
(Community): Mobile testing	3,439
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	



Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility): Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility): Other PITC	
Service Delivery Point (Facility): VCT	
Service Delivery Point (Facility): VMMC	
Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility):	
Index testing	
Service Delivery Point (Facility) by	
Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by	
Age: >15 Outpatient	
Service Delivery Point (Facility) by	
Age: <15 Pediatroc	
Service Delivery Point (Facility) by	
Age: >15 Pediatroc	
Service Delivery Point (Facility) by	
Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by	
Age: >15 Malnutrition facilities	



	T	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of individuals who received	
	T&C services for HIV and received	
	their test results during the past 12	7,823
	months	
	Age/sex: 5-9 Male	
HTC_TST_TA	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	



Age/sex: 5-9 Female	
Age/sex: 10-14 Female	
Age/sex: 15-19 Female	
Age/sex: 20-24 Female	
Age/sex: 25-49 Female	
Age/sex: 50+ Female	
Test Result by Age and Sex: Positive: 10-14 Male	
Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male	
Test Result by Age and Sex: Positive: 25-49 Male	
Test Result by Age and Sex: Positive: 50+ Male	
Test Result by Age and Sex: Positive: 10-14 Female	
Test Result by Age and Sex: Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female	
Test Result by Age and Sex: Positive: 25-49 Female	
Test Result by Age and Sex: Positive: 50+ Female	
Test Result by Age and Sex: Negative: 10-14 Male	
Test Result by Age and Sex: Negative: 15-19 Male	
Test Result by Age and Sex: Negative: 20-24 Male	
Test Result by Age and Sex: Negative: 25-49 Male	



Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: <1 Female	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH	5,930
HQ PERMISSION ONLY: 15+ Male	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	1,893
Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	
and Sex: Positive <15 Male	



Test Result by Aggregated Age	295
and Sex: Positive 15+ Male	255
Test Result by Aggregated Age	
and Sex: Positive <15 Female	
Test Result by Aggregated Age	77
and Sex: Positive 15+ Female	7.7
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	
(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	



Service Delivery Point (Facility): Inpatient	
Service Delivery Point (Facility): Outpatient	
Service Delivery Point (Facility): Pediatric	
Service Delivery Point (Facility): Malnutrition facilities	
Service Delivery Point (Facility): Other PITC	
Service Delivery Point (Facility): VCT	4,275
Service Delivery Point (Facility): VMMC	
Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	107
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	



	Service Delivery Point (Facility) by	
	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	TB_STAT_TA Percentage of	
	registered new and relapsed TB	
	cases with documented HIV status.	n/a
TB_STAT_TA		
10_0171_17		
	Number of registered new and	
	relapsed TB cases with	199
	documented HIV status, during the	



reporting period.	
Total number of registered new and	
relapsed TB cases, during the	241
reporting period.	
Age/Sex: <1 (Numerator: Number	
of registered new and relapsed TB	
cases with documented HIV status,	
during the reporting period)	
Age/Sex: 1-9 (Numerator: Number	
of registered new and relapsed TB	
cases with documented HIV status,	
during the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 15-19 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 20-24 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	



documented HIV status, during the reporting period)	
Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the	
reporting period)	
Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Age/Sex: Female 50+ (Numerator: Number of registered new and	
relapsed TB cases with documented HIV status, during the reporting period)	
Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the	137



reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	60
documented HIV status, during the	
reporting period)	
Result: Known HIV positive at	
service entry	
Result: New HIV positive	
Result: HIV negative	
Age/Sex: <1 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: 1-9 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: Male 10-14	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 15-19	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 20-24	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	



	Age/Sex: Male 25-49	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator:	
	Total number of registered new and	
	relapsed TB cases, during the	
	reporting period)	
	Age/Sex: Female 10-14	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 15-19	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 20-24	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 25-49	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	TB_ART_TA Percentage of	
	HIV-positive new and relapsed	
	registered TB cases on ART during	n/a
	TB treatment	
	The number of registered new and	
TB_ART_TA	relapse TB cases with documented	
	HIV-positive status who are on	12
	ART during TB treatment during	· -
	the reporting period	
	The number of registered new and	
	relapse TB cases with documented	24
	relapse 10 cases with documented	



HIV-positive status during TB treatment during the reporting period Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented		
period Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	HIV-positive status during TB	
Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	treatment during the reporting	
number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	period	
relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	Age/Sex: <1 (Numerator: The	
HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	number of registered new and	
ART during TB treatment during the reporting period) Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	relapse TB cases with documented	
the reporting period) Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	HIV-positive status who are on	
Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	ART during TB treatment during	
number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	the reporting period)	
number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	Age/Sex: 1-9 (Numerator: The	
HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	number of registered new and	
ART during TB treatment during the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	relapse TB cases with documented	
the reporting period) Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	HIV-positive status who are on	
Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	ART during TB treatment during	
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	the reporting period)	
relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	Age/Sex: Male 10-14 (Numerator:	
HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	The number of registered new and	
ART during TB treatment during the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	relapse TB cases with documented	
the reporting period) Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	HIV-positive status who are on	
Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	ART during TB treatment during	
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	the reporting period)	
relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	Age/Sex: Male 15-19 (Numerator:	
HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	The number of registered new and	
ART during TB treatment during the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	relapse TB cases with documented	
the reporting period) Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	HIV-positive status who are on	
Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	ART during TB treatment during	
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	the reporting period)	
relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	Age/Sex: Male 20-24 (Numerator:	
HIV-positive status who are on ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	The number of registered new and	
ART during TB treatment during the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	relapse TB cases with documented	
the reporting period) Age/Sex: Male 25-49 (Numerator: The number of registered new and	HIV-positive status who are on	
Age/Sex: Male 25-49 (Numerator: The number of registered new and	ART during TB treatment during	
The number of registered new and	the reporting period)	
-	Age/Sex: Male 25-49 (Numerator:	
relapse TB cases with documented	The number of registered new and	
	relapse TB cases with documented	



HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 10-14	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 15-19	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 20-24	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 25-49	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	



the reporting period)	
Age/Sex: Female 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	7
HIV-positive status who are on	,
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female <15 (Numerator: The number of	
\	
registered new and relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: The number of	
registered new and relapse TB	_
cases with documented	5
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
On ART: Already on ART	



On ART: New on ART	
Age/Sex: <1 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: 1-9 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 25-49	
(Denominator: The number of	



registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented	



T.	1
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 50+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Male <15	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Male 15+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Female <15	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Female 15+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	



	treatment during the reporting	
	period)	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	
	Screened for TB by Age/Sex: <15 Male	
	Screened for TB by Age/Sex: 15+ Male	295
	Screened for TB by Age/Sex: <15 Female	
TD CODEENDY TA	Screened for TB by Age/Sex: 15+ Female	180
	Screen Results: Screened Positive for TB	9
	TB Positive by Age/Sex: <15 Male	
TB_SCREENDX_TA	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	5
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	5
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	3
TB_SCREEN_TA	TB_SCREEN_TA Percentage of PLHIV who were screened for TB	n/a



	1	
	symptoms at the last clinical visit to	
	an HIV care facility during the	
	reporting period.	
	The number of PLHIV who were	
	screened for TB symptoms at the	475
	last clinical visit to an HIV care	475
	facility during the reporting period	
	Number of HIV positive adults and	
	children who received at least one	
	of the following during the reporting	
	period: clinical assessment (WHO	
	staging) OR CD4 count OR viral	
	load	
	Age: <1	
	Age: 1-4	
	Age: 5-9	
	Age: 10-14	
	Age: 15-19	
	Age: 20+	
	Sum of Age disaggregates	
	Aggregated Age - USE WITH HQ	
	PERMISSION ONLY: <15	
	Aggregated Age - USE WITH HQ	
	PERMISSION ONLY: 15+	
	Sum of Aggregated Age	
	disaggregates	
	Sex: Female	
	Sex: Male	
	Sum of Sex disaggregates	
	Percentage of laboratories and	
	POC testing sites that perform HIV	
LAB_PT_DSD	diagnostic testing that participate	
	and successfully pass in an	
	analyte-specific proficiency testing	



(PT) program HIV serologic/diagnostic testing: Number of laboratories that 1 perform this testing HIV serologic/diagnostic testing: Number of laboratories that 1 participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program
Number of laboratories that perform this testing HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful
Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful
Number of laboratories that achieve acceptable successful
passing criteria in this i i program
CD4: Number of laboratories that perform this testing
CD4: Number of laboratories that participate in this PT program
CD4: Number of laboratories that achieve acceptable successful 1 passing criteria in this PT program
Early infant diagnostics: Number of laboratories that perform this testing
Early infant diagnostics: Number of laboratories that participate in this PT program
Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program
HIV viral load: Number of laboratories that perform this 1 testing
HIV viral load: Number of laboratories that participate in this 1 PT program
HIV viral load: Number of 1



	laboratories that achieve
	acceptable successful passing
	criteria in this PT program
	TB diagnostics (AFB microscopy):
	Number of laboratories that
	perform this testing
	TB diagnostics (AFB microscopy):
	Number of laboratories that
	participate in this PT program
	TB diagnostics (AFB microscopy):
	Number of laboratories that
	achieve acceptable successful
	passing criteria in this PT program
	TB diagnostics (Xpert MTB/RIF):
	Number of laboratories that
	perform this testing
	i i
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that
	participate in this PT program
	TB diagnostics (Xpert MTB/RIF):
	Number of laboratories that
	achieve acceptable successful
	passing criteria in this PT program
	TB diagnostics (Culture/DST):
	Number of laboratories that
	perform this testing
	TB diagnostics (Culture/DST):
	Number of laboratories that
	participate in this PT program
	TB diagnostics (Culture/DST):
	Number of laboratories that
	achieve acceptable successful
	passing criteria in this PT program
	Percentage of laboratories and
LAB_PT_TA	POC testing sites that perform HIV
<u> </u>	



diagnostic testing that participate	
and successfully pass in an	
analyte-specific proficiency testing	
(PT) program	
CD4: Number of laboratories that	
achieve acceptable successful	2
passing criteria in this PT program	
CD4: Number of laboratories that	2
participate in this PT program	2
CD4: Number of laboratories that	_
perform this testing	2
Early infant diagnostics: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
Early infant diagnostics: Number of	
laboratories that participate in this	
PT program	
Early infant diagnostics: Number of	
laboratories that perform this	
testing	
HIV serologic/diagnostic testing:	
Number of laboratories that	0
achieve acceptable successful	6
passing criteria in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	6
participate in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	6
perform this testing	
HIV viral load: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	



HIV viral load: Number of	
laboratories that participate in this	
PT program	
HIV viral load: Number of	
laboratories that perform this	
testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
perform this testing	
TB diagnostics (Culture/DST):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Culture/DST):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (Culture/DST):	
Number of laboratories that	



ı		
	periorii uis testing	



Technical Area Summary Indicators and Targets

Nicaragua

Indicator Number	Label	2017
	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,131
	Total estimated number of key population in the catchment area	22,627
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	6,082



	1
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	4.550
individual and/or small group level	1,559
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	
level HIV preventive interventions	
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	



populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	18,420
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	4,207
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	
Total estimated number of key	



	population in the catchment area)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: REturniong	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	595
	their test results during the past 12	J9J
	months	
HTC_TST_DSD	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
<u> </u>	1 0	



Age/sex: 50+ Male	
Age/sex: 5-9 Female	
Age/sex: 10-14 Female	
Age/sex: 15-19 Female	
Age/sex: 20-24 Female	
Age/sex: 25-49 Female	
Age/sex: 50+ Female	
Test Result by Age and Sex:	
Positive: 10-14 Male	
Test Result by Age and Sex:	
Positive: 15-19 Male	
Test Result by Age and Sex:	
Positive: 20-24 Male	
Test Result by Age and Sex:	
Positive: 25-49 Male	
Test Result by Age and Sex:	
Positive: 50+ Male	
Test Result by Age and Sex:	
Positive: 10-14 Female	
Test Result by Age and Sex:	
Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female	
Test Result by Age and Sex: Positive: 25-49 Female	
Test Result by Age and Sex:	
Positive: 50+ Female	
Test Result by Age and Sex:	
Negative: 10-14 Male	
Test Result by Age and Sex:	
Negative: 15-19 Male	
Test Result by Age and Sex:	
Negative: 20-24 Male	
Test Result by Age and Sex:	



Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male)
Aggregated Age/sex - USE WITH	4,595
HQ PERMISSION ONLY: 15+ Male	+,555
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	0
Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	
and Sex: Positive <15 Male	
Test Result by Aggregated Age	254



and Sex: Positive 15+ Male	
Test Result by Aggregated Age	
and Sex: Positive <15 Female	
Test Result by Aggregated Age	
and Sex: Positive 15+ Female	0
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	
(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	4.440
(Community): Mobile testing	1,149
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	



Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	
Other PITC	
Service Delivery Point (Facility):	2.250
VCT	3,350
Service Delivery Point (Facility):	
VMMC	
Service Delivery Point (Facility):	
PMTCT	
Service Delivery Point (Facility): TB	
Clinics	
Service Delivery Point (Facility):	96
Index testing	90
Service Delivery Point (Facility) by	
Age: <15 Inpatient	
Service Delivery Point (Facility) by	
Age: >15 Inpatient	
Service Delivery Point (Facility) by	
Age: <15 Outpatient	
Service Delivery Point (Facility) by	
Age: >15 Outpatient	
Service Delivery Point (Facility) by	
Age: <15 Pediatroc	
Service Delivery Point (Facility) by	
Age: >15 Pediatroc	
Service Delivery Point (Facility) by	
Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by	



	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	TB_STAT_TA Percentage of	
	registered new and relapsed TB	
	cases with documented HIV status.	n/a
TB_STAT_TA		
	Number of registered new and	
	relapsed TB cases with	140
	documented HIV status, during the	. 10
	reporting period.	



Total number of registered new and	
relapsed TB cases, during the	169
reporting period.	
Age/Sex: <1 (Numerator: Number	
of registered new and relapsed TB	
cases with documented HIV status,	
during the reporting period)	
Age/Sex: 1-9 (Numerator: Number	
of registered new and relapsed TB	
cases with documented HIV status,	
during the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 15-19 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 20-24 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	



	Age/Sex: Female 10-14	
	(Numerator: Number of registered	
	new and relapsed TB cases with	
	documented HIV status, during the	
	reporting period)	
	Age/Sex: Female 15-19	
	(Numerator: Number of registered	
	new and relapsed TB cases with	
	documented HIV status, during the	
	reporting period)	
	Age/Sex: Female 20-24	
	(Numerator: Number of registered	
	new and relapsed TB cases with	
	documented HIV status, during the	
	reporting period)	
	Age/Sex: Female 25-49	
	(Numerator: Number of registered	
	new and relapsed TB cases with	
	documented HIV status, during the	
	reporting period)	
	Age/Sex: Female 50+ (Numerator:	
	Number of registered new and	
	relapsed TB cases with	
	documented HIV status, during the	
	reporting period)	
Ī	Aggregated Age/Sex: Male <15	
	(Numerator: Number of registered	
	new and relapsed TB cases with	1
	documented HIV status, during the	
	reporting period)	
Ī	Aggregated Age/Sex: Male 15+	
	(Numerator: Number of registered	
	new and relapsed TB cases with	97
	documented HIV status, during the	
	reporting period)	
	Aggregated Age/Sex: Female <15	



(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	42
documented HIV status, during the	
reporting period)	
Result: Known HIV positive at	
service entry	
Result: New HIV positive	
Result: HIV negative	
Age/Sex: <1 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: 1-9 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: Male 10-14	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 15-19	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 20-24	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 25-49	
(Denominator: Total number of	



i e			
	registered new and relapsed TB		
	cases, during the reporting period)		
	Age/Sex: Male 50+ (Denominator:		
	Total number of registered new and		
	relapsed TB cases, during the		
	reporting period)		
	Age/Sex: Female 10-14		
	(Denominator: Total number of		
	registered new and relapsed TB		
	cases, during the reporting period)		
	Age/Sex: Female 15-19		
	(Denominator: Total number of		
	registered new and relapsed TB		
	cases, during the reporting period)		
	Age/Sex: Female 20-24		
	(Denominator: Total number of		
	registered new and relapsed TB		
	cases, during the reporting period)		
	Age/Sex: Female 25-49		
	(Denominator: Total number of		
	registered new and relapsed TB		
	cases, during the reporting period)		
	TB_ART_TA Percentage of		
	HIV-positive new and relapsed	/-	
	registered TB cases on ART during	n/a	
	TB treatment		
	The number of registered new and		
	relapse TB cases with documented		
TB_ART_TA	HIV-positive status who are on	7	
	ART during TB treatment during		
	the reporting period		
	The number of registered new and		
	relapse TB cases with documented	40	
1		16	
	HIV-positive status during TB		
TB_ART_TA	registered TB cases on ART during TB treatment The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period The number of registered new and relapse TB cases with documented	n/a 7	





the reporting period)	
Age/Sex: Male 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 10-14	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 15-19	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 20-24	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 25-49	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 50+ (Numerator:	



The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	4
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	3
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
On ART: Already on ART	
On ART: New on ART	
Age/Sex: <1 (Denominator: The	



number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: 1-9 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
,	
Age/Sex: Male 15-19 (Denominator: The number of	
`	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 25-49	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	



i T	\neg
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 50+ (Denominator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 25-49	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
1	



period)
Age/Sex: Female 50+
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Aggregated Age/Sex: Male <15
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Aggregated Age/Sex: Male 15+
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Aggregated Age/Sex: Female <15
(Denominator: The number of
`
registered new and relapse TB cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Aggregated Age/Sex: Female 15+
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)



	The number of PLHIV who were	
	screened for TB symptoms at the	
	last clinical visit at a HIV facility	
	during the reporting period.	
	Screened for TB by Age/Sex: <15	
	Male	
	Screened for TB by Age/Sex: 15+	405
	Male	135
	Screened for TB by Age/Sex: <15	
	Female	
	Screened for TB by Age/Sex: 15+	400
	Female	100
	Screen Results: Screened Positive	_
	for TB	5
TO CODEFINE TA	TB Positive by Age/Sex: <15 Male	
TB_SCREENDX_TA	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15	
	Female	
	TB Positive by Age/Sex: 15+	
	Female	
	[Sub-Disagg of Screen Results]	
	Specimen Sent: Specimen sent for	3
	bacteriologic diagnosis of active TB	
	[Sub-disagg of Specimen Sent]	0
	Diagnostic Test: Smear Only	3
	[Sub-disagg of Specimen Sent]	
	Diagnostic Test: Xpert MTB/RIF	3
	assay	
	[Sub-disagg of Specimen Sent]	
	Diagnostic Test: Other (Not Xpert)	
	TB_SCREEN_TA Percentage of	
TR SCREEN TA	PLHIV who were screened for TB	n/a
TB_SCREEN_TA	symptoms at the last clinical visit to	II/a
	an HIV care facility during the	



	reporting period.	
	The number of PLHIV who were	
	screened for TB symptoms at the	235
	last clinical visit to an HIV care	235
	facility during the reporting period	
	Number of HIV positive adults and	
	children who received at least one	
	of the following during the reporting	
	period: clinical assessment (WHO	
	staging) OR CD4 count OR viral	
	load	
	Age: <1	
	Age: 1-4	
	Age: 5-9	
	Age: 10-14	
	Age: 15-19	
	Age: 20+	
	Sum of Age disaggregates	
	Aggregated Age - USE WITH HQ	
	PERMISSION ONLY: <15	
	Aggregated Age - USE WITH HQ	
	PERMISSION ONLY: 15+	
	Sum of Aggregated Age	
	disaggregates	
	Sex: Female	
	Sex: Male	
	Sum of Sex disaggregates	
	Number of adults and children	
	receiving antiretroviral therapy	1,438
	(ART)	
TX_CURR_TA	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	



	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	718
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	720
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	1,438
	Sum of Aggregated Age/Sex	4 400
	disaggregates	1,438
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1	
	and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_TA	Number of adults and children	214



newly enrolled on antiretroviral	
therapy (ART)	
By Age/Sex: <1	
By Age/Sex: 1-9	
By Age/Sex: <1 Male	
By Age/Sex: 1-4 Male	
By Age/Sex: 5-9 Male	
By Age/Sex: 10-14 Male	
By Age/Sex: 15-19 Male	
By Age/Sex: 20-24 Male	
By Age/Sex: 25-49 Male	
By Age/Sex: 50+ Male	
By Age/Sex: <1 Female	
By Age/Sex: 1-4 Female	
By Age/Sex: 5-9 Female	
By Age/Sex: 10-14 Female	
By Age/Sex: 15-19 Female	
By Age/Sex: 20-24 Female	
By Age/Sex: 25-49 Female	
By Age/Sex: 50+ Female	
Sum of Age/Sex disaggregates	
Aggregated Grouping by Age: <1	
Aggregated Grouping by Age: <1 Male	
Aggregated Grouping by Age/Sex: <15 Male	
Aggregated Grouping by Age/Sex: 1-14 Male	
Aggregated Grouping by Age/Sex: 15+ Male	106
Aggregated Grouping by Age: <1 Female	
Aggregated Grouping by Age/Sex:	



	<15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	108
	Sum of Aggregated Age/Sex disaggregates	214
	Pregnancy status	
	Breastfeeding status	
	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	5
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	4
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
	CD4: Number of laboratories that perform this testing	4
	CD4: Number of laboratories that participate in this PT program	4
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
	Early infant diagnostics: Number of laboratories that perform this testing	



Early infant diagnostics: Number of	
laboratories that participate in this	
PT program	
Early infant diagnostics: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
HIV viral load: Number of	
laboratories that perform this	1
testing	
HIV viral load: Number of	
laboratories that participate in this	1
PT program	
HIV viral load: Number of	
laboratories that achieve	4
acceptable successful passing	1
criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	



	achieve acceptable successful	
	passing criteria in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	perform this testing	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	participate in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	achieve acceptable successful	
	passing criteria in this PT program	
	Percentage of laboratories and	
	POC testing sites that perform HIV	
	diagnostic testing that participate	
	and successfully pass in an	
	analyte-specific proficiency testing	
	(PT) program	
	CD4: Number of laboratories that	
	achieve acceptable successful	
	passing criteria in this PT program	
	CD4: Number of laboratories that	
	participate in this PT program	
LAB PT TA	CD4: Number of laboratories that	
	perform this testing	
	Early infant diagnostics: Number of	
	laboratories that achieve	
	acceptable successful passing	
	criteria in this PT program	
	Early infant diagnostics: Number of	
	laboratories that participate in this	
	PT program	
	Early infant diagnostics: Number of	
	laboratories that perform this	
	testing	



HIV serologic/diagnostic testing:	
Number of laboratories that	1
achieve acceptable successful	l l
passing criteria in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	1
participate in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	3
perform this testing	
HIV viral load: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
HIV viral load: Number of	
laboratories that participate in this	
PT program	
HIV viral load: Number of	
laboratories that perform this	
testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	



	,
Number of laboratories that participate in this PT program	
TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
TB diagnostics (Culture/DST): Number of laboratories that perform this testing	



Technical Area Summary Indicators and Targets

Panama

Indicator Number	Label	2017	
	KP_PREV_DSD Percentage of key		
	populations reached with individual		
	and/or small group level HIV	n/a	
	preventive interventions that are	n/a	
	based on evidence and/or meet the		
	minimum standards required (DSD)		
	Number of key populations reached		
	with individual and/or small group		
	level HIV preventive interventions	E 606	
	that are based on evidence and/or	5,606	
	meet the minimum standards		
	required		
	Total estimated number of key	40.444	
	population in the catchment area	13,144	
KP_PREV_DSD	By key population type: Men who		
	have sex with men who are sex		
	workers (Numerator: Number of		
	key populations reached with		
	individual and/or small group level		
	HIV preventive interventions that		
	are based on evidence and/or meet		
	the minimum standards required)		
	By key population type: Men who		
	have sex with men who are NOT		
	sex workers (Numerator: Number		
	of key populations reached with	5,540	
	individual and/or small group level		
	HIV preventive interventions that		
	are based on evidence and/or meet		



the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	00
individual and/or small group level	66
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	
level HIV preventive interventions	
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	



	copulations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	
	pased on evidence and/or meet the	
1	minimum standards required)	
	By key population type: People in	
	orisons and enclosed settings	
	(Numerator: Number of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	
	pased on evidence and/or meet the	
	minimum standards required)	
	By key population type: Men who	
	nave sex with men who are sex	
,	workers (Denominator: Total	
	estimated number of key	
	population in the catchment area	
	By key population type: Men who	
	nave sex with men who are NOT	
:	sex workers (Denominator: Total	13,144
	estimated number of key	
	population in the catchment area)	
	By key population type:	
ŀ	Transgender who are sex workers	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type:	
	Transgender who are NOT sex	
,	workers (Denominator: Total	
	estimated number of key	
	population in the catchment area)	
	By key population type: Female	
:	sex workers (FSW) (Denominator:	
_	Total estimated number of key	



	population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV	
KP_PREV_TA	preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group	3,845



level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
Total estimated number of key population in the catchment area	7,724
By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who inject drugs (Male PWID)	



(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Females	
who inject drugs (Female PWID)	
Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Men who	
have sex with men and are sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or med	et
the minimum standards required)	
By key population type: Men who	
have sex with men and are NOT	
sex workers (Numerator: Number	
of key populations reached with	
individual and/or small group level	3,786
HIV preventive interventions that	
are based on evidence and/or me	at .
the minimum standards required)	
· · · ·	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individua	ai
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet th	е
minimum standards required)	
By key population type:	
Transgender who are NOT sex	59
workers (Numerator: Number of	
key populations reached with	



individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men and are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Men who	
have sex with men and are NOT	
sex workers (Denominator: Total	7,468
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	256
estimated number of key	
population in the catchment area)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Denominator: Total estimated	
number of key population in the	



	catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: Returning	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	3,404
	their test results during the past 12 months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
 HTC_TST_DSD	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex:	
	Positive: 10-14 Male	
	Test Result by Age and Sex:	
	Positive: 15-19 Male	
	Test Result by Age and Sex:	
	Positive: 20-24 Male	



Test Result by Age and Sex:	
Positive: 25-49 Male	
Test Result by Age and Sex:	
Positive: 50+ Male	
Test Result by Age and Sex:	
Positive: 10-14 Female	
Test Result by Age and Sex:	
Positive: 15-19 Female	
Test Result by Age and Sex:	
Positive: 20-24 Female	
Test Result by Age and Sex:	
Positive: 25-49 Female	
Test Result by Age and Sex:	
Positive: 50+ Female	
Test Result by Age and Sex:	
Negative: 10-14 Male	
Test Result by Age and Sex:	
Negative: 15-19 Male	
Test Result by Age and Sex:	
Negative: 20-24 Male	
Test Result by Age and Sex:	
Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	



Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,284
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	120
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	
Test Result by Aggregated Age and Sex: Positive 15+ Male	165
Test Result by Aggregated Age and Sex: Positive <15 Female	
Test Result by Aggregated Age and Sex: Positive 15+ Female	6
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	
(Community): Index testing	
Service Delivery Point (Community): Homebased testing	



Service Delivery Point	2 904
(Community): Mobile testing	2,804
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	
Other PITC	
Service Delivery Point (Facility):	
VCT	
Service Delivery Point (Facility):	
VMMC	



Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by Age: <15 VMMC	
Service Delivery Point (Facility) by Age: >15 VMMC	



	1	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of individuals who received	
	T&C services for HIV and received	2,302
	their test results during the past 12	2,002
	months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
HTC_TST_TA	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex:	



Positive: 20-24 Male	
Test Result by Age and Sex:	
Positive: 25-49 Male	
Test Result by Age and Sex:	
Positive: 50+ Male	
Test Result by Age and Sex:	
Positive: 10-14 Female	
Test Result by Age and Sex:	
Positive: 15-19 Female	
Test Result by Age and Sex:	
Positive: 20-24 Female	
Test Result by Age and Sex:	
Positive: 25-49 Female	
Test Result by Age and Sex:	
Positive: 50+ Female	
Test Result by Age and Sex:	
Negative: 10-14 Male	
Test Result by Age and Sex:	
Negative: 15-19 Male	
Test Result by Age and Sex:	
Negative: 20-24 Male	
Test Result by Age and Sex:	
Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: <1 Female	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	



Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,302
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	
Test Result by Aggregated Age and Sex: Positive 15+ Male	115
Test Result by Aggregated Age and Sex: Positive <15 Female	
Test Result by Aggregated Age and Sex: Positive 15+ Female	0
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	



(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	
Other PITC	
Service Delivery Point (Facility):	2,243



VCT	
Service Delivery Point (Facility):	
VMMC	
Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	59
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by	



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	110
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	134
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



Age/Sex: Male 10-14 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 15-19 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 20-24 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 10-14	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 15-19	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 20-24	



(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 25-49	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	78
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	32
documented HIV status, during the	
reporting period)	
Result: Known HIV positive at	
service entry	



)	
Result: New HIV positive	
Result: HIV negative	
Age/Sex: <1 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: 1-9 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: Male 10-14	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 15-19	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 20-24	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 25-49	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 50+ (Denominator:	
Total number of registered new and	d l
relapsed TB cases, during the	
reporting period)	
Age/Sex: Female 10-14	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Female 15-19	



	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 20-24	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 25-49	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	TB_ART_TA Percentage of	
	HIV-positive new and relapsed	
	registered TB cases on ART during	n/a
	TB treatment	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	6
	ART during TB treatment during	· ·
	the reporting period	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status during TB	10
TB_ART_TA	treatment during the reporting	10
ID_AKI_IA	period	
	•	
	Age/Sex: <1 (Numerator: The	
	number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The	
	number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during	



the reporting period)	
the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 15-19 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 20-24 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 25-49 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 10-14	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	



_	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 15-19	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 20-24	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 25-49	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
line reporting period)	



Aggregated Age/Sex: Male 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	4
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	2
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
On ART: Already on ART	
On ART: New on ART	
Age/Sex: <1 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: 1-9 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
 Age/Sex: Male 10-14	
·	· · · · · · · · · · · · · · · · · · ·



(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of		
cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50-4 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	(Denominator: The number of	
HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	registered new and relapse TB	
treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	cases with documented	
period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	HIV-positive status during TB	
Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	treatment during the reporting	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	period)	
registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	Age/Sex: Male 15-19	
cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	(Denominator: The number of	
HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	registered new and relapse TB	
treatment during the reporting period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	cases with documented	
period) Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	HIV-positive status during TB	
Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	treatment during the reporting	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	period)	
registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	Age/Sex: Male 20-24	
cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	(Denominator: The number of	
HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	registered new and relapse TB	
treatment during the reporting period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	cases with documented	
period) Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	HIV-positive status during TB	
Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	treatment during the reporting	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	period)	
registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	Age/Sex: Male 25-49	
cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	(Denominator: The number of	
HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	registered new and relapse TB	
treatment during the reporting period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	cases with documented	
period) Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	HIV-positive status during TB	
Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	treatment during the reporting	
The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	period)	
The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	Age/Sex: Male 50+ (Denominator:	
HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of		
treatment during the reporting period) Age/Sex: Female 10-14 (Denominator: The number of	relapse TB cases with documented	
period) Age/Sex: Female 10-14 (Denominator: The number of	HIV-positive status during TB	
Age/Sex: Female 10-14 (Denominator: The number of	treatment during the reporting	
(Denominator: The number of	period)	
(Denominator: The number of	Age/Sex: Female 10-14	
l'		
registered new and relapse TB	registered new and relapse TB	



cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
IAME/SEY: FEMSIE 75-49	
Age/Sex: Female 25-49	
(Denominator: The number of	
(Denominator: The number of registered new and relapse TB	
(Denominator: The number of registered new and relapse TB cases with documented	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 50+	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 50+ (Denominator: The number of	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Aggregated Age/Sex: Male <15	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: The number of	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Aggregated Age/Sex: Male <15	



	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	Aggregated Age/Sex: Male 15+	
	(Denominator: The number of	
	registered new and relapse TB	
	cases with documented	
	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	Aggregated Age/Sex: Female <15	
	(Denominator: The number of	
	registered new and relapse TB	
	cases with documented	
	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	· · · · ·	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of	
	,	
	registered new and relapse TB	
	cases with documented	
	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	The number of PLHIV who were	
	screened for TB symptoms at the	
	last clinical visit at a HIV facility	
	during the reporting period.	
	Screened for TB by Age/Sex: <15	
TB_SCREENDX_TA	Male	
	Screened for TB by Age/Sex: 15+	310
	Male	310
	Screened for TB by Age/Sex: <15	
	Female	



	Female	
	Screen Results: Screened Positive for TB	10
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	6
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	6
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	6
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	
	TB_SCREEN_TA Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a
TB_SCREEN_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	530
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	
	Age: <1	



	1	
	Age: 1-4	
	Age: 5-9	
	Age: 10-14	
	Age: 15-19	
	Age: 20+	
	Sum of Age disaggregates	
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	
	Sum of Aggregated Age disaggregates	
	Sex: Female	
	Sex: Male	
	Sum of Sex disaggregates	
	Number of adults and children receiving antiretroviral therapy	6,582
	(ART)	
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
TX_CURR_TA	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	



	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	4,190
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	2,392
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	6,582
	Sum of Aggregated Age/Sex disaggregates	6,582
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	230
	By Age/Sex: <1	
	By Age/Sex: 1-9	
TX_NEW_TA	By Age/Sex: <1 Male	
_	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	



	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	211
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	19
	Sum of Aggregated Age/Sex disaggregates	230
	Pregnancy status	
	Breastfeeding status	
LAB_PT_DSD	Percentage of laboratories and	
	i crocinage of laboratories and	



POC testing sites that perform HIV	
diagnostic testing that participate	
and successfully pass in an	
analyte-specific proficiency testing	
(PT) program	
HIV serologic/diagnostic testing:	
Number of laboratories that 1	
perform this testing	
HIV serologic/diagnostic testing:	
Number of laboratories that 1	
participate in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
CD4: Number of laboratories that	
perform this testing	
CD4: Number of laboratories that	
participate in this PT program	
CD4: Number of laboratories that	
achieve acceptable successful 1	
passing criteria in this PT program	
Early infant diagnostics: Number of	
laboratories that perform this	
testing	
Early infant diagnostics: Number of	
laboratories that participate in this	
PT program	
Early infant diagnostics: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
HIV viral load: Number of	
laboratories that perform this 1	
testing	



T.	
HIV viral load: Number of	
laboratories that participate in this	1
PT program	
HIV viral load: Number of	
laboratories that achieve	4
acceptable successful passing	1
criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Culture/DST):	
Number of laboratories that	
perform this testing	
TB diagnostics (Culture/DST):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (Culture/DST):	
Number of laboratories that	
radinor of laboratories triat	



	1	
	achieve acceptable successful	
	passing criteria in this PT program	
	Percentage of laboratories and	
	POC testing sites that perform HIV	
	diagnostic testing that participate	
	and successfully pass in an	
	analyte-specific proficiency testing	
	(PT) program	
	CD4: Number of laboratories that	
	achieve acceptable successful	1
	passing criteria in this PT program	
	CD4: Number of laboratories that	
	participate in this PT program	1
	CD4: Number of laboratories that	
	perform this testing	1
	Early infant diagnostics: Number of	
	laboratories that achieve	
	acceptable successful passing	
LAB_PT_TA	criteria in this PT program	
	Early infant diagnostics: Number of	
	laboratories that participate in this	
	PT program	
	Early infant diagnostics: Number of	
	laboratories that perform this	
	testing	
	HIV serologic/diagnostic testing:	
	Number of laboratories that	
	achieve acceptable successful	5
	passing criteria in this PT program	
	HIV serologic/diagnostic testing:	
	Number of laboratories that	5
	participate in this PT program	5
	HIV serologic/diagnostic testing: Number of laboratories that	E
		5
	perform this testing	



HIV viral load: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
HIV viral load: Number of	
laboratories that participate in this	
PT program	
HIV viral load: Number of	
laboratories that perform this	
testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
perform this testing	
TB diagnostics (Culture/DST):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Culture/DST):	



Number of laboratories that
participate in this PT program
TB diagnostics (Culture/DST):
Number of laboratories that
perform this testing



Technical Area Summary Indicators and Targets

Central America Region

Indicator Number	Label	2017	
	PP_PREV_DSD Percentage of the		
	target population who completed a		
	standardized HIV prevention	n/a	
	intervention including the minimum	II/a	
	components during the reporting		
	period (DSD)		
	Number of the target population		
	who completed a standardized HIV		
	prevention intervention including	2,615	
	the minimum components during		
	the reporting period.		
	Total number of people in the	2,615	
	target population		
PP_PREV_DSD	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Denominator: Age/sex: 10-14 Male		
	Denominator: Age/sex: 15-19 Male		
	Denominator: Age/sex: 20-24 Male		
	Denominator: Age/sex: 25-49 Male		



	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	45,694
	Total estimated number of key population in the catchment area	88,496
	By key population type: Men who	



<u> </u>	
have sex with men who are sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Numerator: Number	
of key populations reached with	
individual and/or small group level	40,788
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	1,846
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	2,570
with individual and/or small group	2,370
level HIV preventive interventions	
1.5.5.7.1.7 proformitor mitor vormono	



I .	
that are based on evidence and/or meet the minimum standards required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
, , , , , , , , , , , , , , , , , , , ,	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	65,131
sex workers (Denominator: Total	·
estimated number of key	



population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	4,662
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	0.005
Total estimated number of key	2,625
population in the catchment area)	
By key population type: Males who	
inject drugs (Male PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Females	
who inject drugs (Female PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: People in	
prisons and enclosed settings	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By Service: KP known status	
By Service: KP was tested as part	
of the program and/or KP was	
referred for testing as part of the	
program	



	By New Client Status: New	
	beneficiary	
	By New Client Status: REturniong	
	beneficiary within the current report	
	period	
	KP_PREV_TA Percentage of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	n/a
	based on evidence and/or meet the	
	minimum standards required	
	(TA-only)	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	
	that are based on evidence and/or	19,345
	meet the minimum standards	
	required	
	Total estimated number of key	30,055
	population in the catchment area	
KP_PREV_TA	By key population type: Female	
	sex workers (FSW) (Numerator:	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	2,842
	that are based on evidence and/or	
	meet the minimum standards	
	required)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Numerator: Number of key	
	populations reached with individual	
	and/or small group level HIV	0
	preventive interventions that are	
	'	
	based on evidence and/or meet the	
	minimum standards required)	



B	By key population type: Females	
w	vho inject drugs (Female PWID)	
(1	Numerator: Number of key	
p	populations reached with individual	0
a	and/or small group level HIV	0
p	preventive interventions that are	
b	pased on evidence and/or meet the	
n	ninimum standards required)	
B	By key population type: Female	
	sex workers (FSW) (Denominator:	
	Total estimated number of key	7,707
	population in the catchment area)	
	By key population type: Males who	
	nject drugs (Male PWID)	
	Denominator: Total estimated	
<u>'</u>	number of key population in the	
	catchment area)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	Denominator: Total estimated	
<u> </u>	number of key population in the	
	catchment area)	
	·	
	By key population type: Men who	
	nave sex with men and are sex	
	vorkers (Numerator: Number of	
	key populations reached with	0
	ndividual and/or small group level	
	HIV preventive interventions that are based on evidence and/or meet	
	he minimum standards required)	
	By key population type: Men who	
	nave sex with men and are NOT	
	sex workers (Numerator: Number	15,836
	of key populations reached with	•
	ndividual and/or small group level	
	HIV preventive interventions that	



are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	2
and/or small group level HIV	0
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	667
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men and are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Men who	
have sex with men and are NOT	
sex workers (Denominator: Total	21,729
estimated number of key	,
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	610
Transgender who are NOT sex	619
workers (Denominator: Total	



	1	
	estimated number of key	
	population in the catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Numerator: Number of key	
	populations reached with individual	0
	and/or small group level HIV	U
	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: Returning	
	beneficiary within the current report	
	period	
	Number of individuals who received	
HTC_TST_DSD	T&C services for HIV and received	07.475
	their test results during the past 12	27,475
	months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	1. 13.5. 30.11. 30.11. 11. 11. 11. 11. 11. 11. 11. 11. 11	



Age/sex: 5-9 Female	
Age/sex: 10-14 Female	
Age/sex: 15-19 Female	
Age/sex: 20-24 Female	
Age/sex: 25-49 Female	
Age/sex: 50+ Female	
Test Result by Age and Sex: Positive: 10-14 Male	
Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male	
Test Result by Age and Sex: Positive: 25-49 Male	
Test Result by Age and Sex: Positive: 50+ Male	
Test Result by Age and Sex: Positive: 10-14 Female	
Test Result by Age and Sex: Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female	
Test Result by Age and Sex: Positive: 25-49 Female	
Test Result by Age and Sex: Positive: 50+ Female	
Test Result by Age and Sex: Negative: 10-14 Male	
Test Result by Age and Sex: Negative: 15-19 Male	
Test Result by Age and Sex: Negative: 20-24 Male	
Test Result by Age and Sex: Negative: 25-49 Male	



Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex: Negative: 10-14 Female	
Test Result by Age and Sex: Negative: 15-19 Female	
Test Result by Age and Sex: Negative: 20-24 Female	
Test Result by Age and Sex: Negative: 25-49 Female	
Test Result by Age and Sex: Negative: 50+ Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	25,444
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,031
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	
Test Result by Aggregated Age and Sex: Positive 15+ Male	1,310



Test Result by Aggregated Age	
and Sex: Positive <15 Female	
Test Result by Aggregated Age and Sex: Positive 15+ Female	83
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	
(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	40.000
(Community): Mobile testing	16,393
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	



Service Delivery Point (Facility): Outpatient	
Service Delivery Point (Facility): Pediatric	
Service Delivery Point (Facility): Malnutrition facilities	
Service Delivery Point (Facility): Other PITC	
Service Delivery Point (Facility): VCT	8,315
Service Delivery Point (Facility): VMMC	
Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	227
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	



	1	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of individuals who received	
	T&C services for HIV and received	12,299
	their test results during the past 12	12,233
	months	
	Age/sex: 5-9 Male	
HTC_TST_TA	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Mycroex. Jut Ividie	



Age/sex: 5-9 Female	
Age/sex: 10-14 Female	
Age/sex: 15-19 Female	
Age/sex: 20-24 Female	
Age/sex: 25-49 Female	
Age/sex: 50+ Female	
Test Result by Age and Sex: Positive: 10-14 Male	
Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male	
Test Result by Age and Sex: Positive: 25-49 Male	
Test Result by Age and Sex: Positive: 50+ Male	
Test Result by Age and Sex: Positive: 10-14 Female	
Test Result by Age and Sex: Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female	
Test Result by Age and Sex: Positive: 25-49 Female	
Test Result by Age and Sex: Positive: 50+ Female	
Test Result by Age and Sex: Negative: 10-14 Male	
Test Result by Age and Sex: Negative: 15-19 Male	
Test Result by Age and Sex: Negative: 20-24 Male	
Test Result by Age and Sex: Negative: 25-49 Male	



Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: <1 Female	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH	10,095
HQ PERMISSION ONLY: 15+ Male	-,
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	2,204
Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	
and Sex: Positive <15 Male	



Test Result by Aggregated Age and Sex: Positive 15+ Male	508
Test Result by Aggregated Age	
and Sex: Positive <15 Female	
Test Result by Aggregated Age	91
and Sex: Positive 15+ Female	
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	
(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	



Service Delivery Point (Facility):	
Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	
Other PITC	
Service Delivery Point (Facility):	8,635
VCT	0,033
Service Delivery Point (Facility):	
VMMC	
Service Delivery Point (Facility):	
PMTCT	
Service Delivery Point (Facility): TB	
Clinics	
Service Delivery Point (Facility):	223
Index testing	225
Service Delivery Point (Facility) by	
Age: <15 Inpatient	
Service Delivery Point (Facility) by	
Age: >15 Inpatient	
Service Delivery Point (Facility) by	
Age: <15 Outpatient	
Service Delivery Point (Facility) by	
Age: >15 Outpatient	
Service Delivery Point (Facility) by	
Age: <15 Pediatroc	
Service Delivery Point (Facility) by	
Age: >15 Pediatroc	
Service Delivery Point (Facility) by	
Age: <15 Malnutrition facilities	



	Service Delivery Point (Facility) by	
	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	TB_STAT_TA Percentage of	
	registered new and relapsed TB	
	cases with documented HIV status.	n/a
TR STAT TA		
TB_STAT_TA		
	Number of registered new and	
	relapsed TB cases with	934
	documented HIV status, during the	



reporting period.	
Total number of registered new and	
relapsed TB cases, during the	1,130
reporting period.	·
Age/Sex: <1 (Numerator: Number	
of registered new and relapsed TB	
cases with documented HIV status,	
during the reporting period)	
Age/Sex: 1-9 (Numerator: Number	
of registered new and relapsed TB	
cases with documented HIV status,	
during the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 15-19 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 20-24 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	



documented HIV status, during the reporting period)	
Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the	646



1
280



	Age/Sex: Male 25-49	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator:	
	Total number of registered new and	
	relapsed TB cases, during the	
	reporting period)	
	Age/Sex: Female 10-14	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 15-19	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 20-24	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 25-49	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	TB_ART_TA Percentage of	
	HIV-positive new and relapsed	,
	registered TB cases on ART during	n/a
	TB treatment	
	The number of registered new and	
TB_ART_TA	relapse TB cases with documented	
	HIV-positive status who are on	36
	ART during TB treatment during	
	the reporting period	
	The number of registered new and	
	relapse TB cases with documented	79



HIV-positive status during TB	
treatment during the reporting	
period	
Age/Sex: <1 (Numerator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: 1-9 (Numerator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 15-19 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 20-24 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 25-49 (Numerator:	
The number of registered new and	
 relapse TB cases with documented	
-	



_	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 10-14	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 15-19	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 20-24	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 25-49	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	



the reporting period) Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 422 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period) On ART: Already on ART	T.	
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented	the reporting period)	
relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period) ART during TB treatment during the reporting period)	Age/Sex: Female 50+ (Numerator:	
HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	The number of registered new and	
ART during TB treatment during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	relapse TB cases with documented	
the reporting period) Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)	HIV-positive status who are on	
the reporting period) Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)	ART during TB treatment during	
Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)	Aggregated Age/Sex: Male <15	
registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)		
cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)	`	
HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)	·	
Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented third period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
(Numerator: The number of registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
registered new and relapse TB cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
cases with documented 22 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)	,	
HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		22
ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		22
the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	l'	
HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)	·	
Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
(Numerator: The number of registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
registered new and relapse TB cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)		
cases with documented 14 HIV-positive status who are on ART during TB treatment during the reporting period)	, and the second	
HIV-positive status who are on ART during TB treatment during the reporting period)	,	
ART during TB treatment during the reporting period)		14
the reporting period)		
On ART: Already on ART		
	On ART: Already on ART	



On ART: New on ART Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	
relapse TB cases with documented HIV-positive status during TB treatment during the reporting	
HIV-positive status during TB treatment during the reporting	
treatment during the reporting	
period)	
Age/Sex: 1-9 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 25-49	
(Denominator: The number of	



	,
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 50+ (Denominator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 20-24	
(Denominator: The number of	
`	
registered new and relapse TB	
`	
registered new and relapse TB	
registered new and relapse TB cases with documented	
registered new and relapse TB cases with documented HIV-positive status during TB	
registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	
registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 25-49	
registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Female 25-49 (Denominator: The number of	



HIV-positive status during TB treatment during the reporting	
period)	
Age/Sex: Female 50+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Male <15	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Male 15+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Female <15 (Denominator: The number of	
`	
registered new and relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Female 15+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	



	treatment during the reporting	
	period)	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	
	Screened for TB by Age/Sex: <15 Male	
	Screened for TB by Age/Sex: 15+ Male	1,515
	Screened for TB by Age/Sex: <15 Female	
	Screened for TB by Age/Sex: 15+ Female	870
	Screen Results: Screened Positive for TB	47
TB_SCREENDX_TA	TB Positive by Age/Sex: <15 Male	
ID_SONELNDA_IA	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	27
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	27
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	16
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	11
TB_SCREEN_TA	TB_SCREEN_TA Percentage of PLHIV who were screened for TB	n/a



symptoms at the last clinical an HIV care facility during the reporting period. The number of PLHIV who wascreened for TB symptoms a last clinical visit to an HIV care facility during the reporting period.	e vere
reporting period. The number of PLHIV who wascreened for TB symptoms a last clinical visit to an HIV ca	vere
The number of PLHIV who wascreened for TB symptoms a last clinical visit to an HIV ca	
screened for TB symptoms a last clinical visit to an HIV ca	
last clinical visit to an HIV ca	at the
	2 205
facility during the reporting of	2,385
racinty during the reporting p	eriod
Number of HIV positive adult	ts and
children who received at least	st one
of the following during the re	porting
period: clinical assessment (WHO
staging) OR CD4 count OR v	viral
load	
Age: <1	
Age: 1-4	
Age: 5-9	
Age: 10-14	
Age: 15-19	
Age: 20+	
Sum of Age disaggregates	
Aggregated Age - USE WITH	H HQ
PERMISSION ONLY: <15	
Aggregated Age - USE WITH	H HQ
PERMISSION ONLY: 15+	
Sum of Aggregated Age	
disaggregates	
Sex: Female	
Sex: Male	
Sum of Sex disaggregates	
Number of adults and childre	en
receiving antiretroviral therap	py 18,194
TX_CURR_TA (ART)	
Age/Sex: <1 Male	
Age/Sex: 1-4 Male	



Age/Sex: 5-14 Male	
Age/Sex: 15-19 Male	
Age/Sex: 20+ Male	
Age/Sex: <1 Female	
Age/Sex: 1-4 Female	
Age/Sex: 5-14 Female	
Age/Sex: 15-19 Female	
Age/Sex: 20+ Female	
Sum of Age/Sex disaggregations	
Aggregated Age/Sex: <1 Male	
Aggregated Age/Sex: <1 Female	
Aggregated Age/Sex: <15 Male	
Aggregated Age/Sex: 1-14 Male	
Aggregated Age/Sex: 15+ Male	10,725
Aggregated Age/Sex: <15 Female	
Aggregated Age/Sex: 1-14 Female	
Aggregated Age/Sex: 15+ Female	7,469
Sum of Aggregated Age/Sex <15	
Sum of Aggregated Age/Sex 15+	18,194
Sum of Aggregated Age/Sex	10.104
disaggregates	18,194
Age/Sex: <1	
Age/Sex: 1-9	
Age/Sex: 10-14 Male	
Age/Sex: 10-14 Female	
Sum of Aggregated Age/Sex (<1	
and 1-14) <15	
Age/Sex: 20-24 Male	
Age/Sex: 25-49 Male	
Age/Sex: 50+ Male	
Age/Sex: 20-24 Female	
Age/Sex: 25-49 Female	



	Age/Sex: 50+ Female	
	Number of adults and children	
	newly enrolled on antiretroviral therapy (ART)	854
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
TX_NEW_TA	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	0
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	727
	Aggregated Grouping by Age: <1	



	Female	
	Aggregated Grouping by Age/Sex: <15 Female	0
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	127
	Sum of Aggregated Age/Sex disaggregates	854
	Pregnancy status	
	Breastfeeding status	
	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an	
LAB_PT_DSD	analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	17
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	13
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	17
	CD4: Number of laboratories that perform this testing	12
	CD4: Number of laboratories that participate in this PT program	12
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	12



Early infant diagnostics: Number of	
laboratories that perform this	
testing	
Early infant diagnostics: Number of	
laboratories that participate in this	
PT program	
Early infant diagnostics: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
HIV viral load: Number of	
laboratories that perform this	6
testing	
HIV viral load: Number of	
laboratories that participate in this	6
PT program	
HIV viral load: Number of	
laboratories that achieve	0
acceptable successful passing	6
criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	



	participate in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	
	achieve acceptable successful	
	passing criteria in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	perform this testing	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	participate in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	achieve acceptable successful	
	passing criteria in this PT program	
	Percentage of laboratories and	
	POC testing sites that perform HIV	
	diagnostic testing that participate	
	and successfully pass in an	
	analyte-specific proficiency testing	
	(PT) program	
	CD4: Number of laboratories that	
	achieve acceptable successful	3
	passing criteria in this PT program	
	CD4: Number of laboratories that	
LAB_PT_TA	participate in this PT program	3
	CD4: Number of laboratories that	
	perform this testing	3
	Early infant diagnostics: Number of	
	laboratories that achieve	
	acceptable successful passing	
	criteria in this PT program	
	Early infant diagnostics: Number of	
	laboratories that participate in this	
	PT program	
	l 5.08.000	



Early infant diagnostics: Number of	
laboratories that perform this	
testing	
HIV serologic/diagnostic testing:	
Number of laboratories that	00
achieve acceptable successful	20
passing criteria in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	19
participate in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	24
perform this testing	
HIV viral load: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
HIV viral load: Number of	
laboratories that participate in this	
PT program	
HIV viral load: Number of	
laboratories that perform this	
testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	



achieve acceptable successful passing criteria in this PT program	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that participate in this PT program	
TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (Culture/DST): Number of laboratories that	
participate in this PT program TB diagnostics (Culture/DST):	
Number of laboratories that perform this testing	



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
13082	Population Services International	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	2,389,875
13445	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	5,068,524
14401	U.S. Department of Defense Naval Health Research Center	Own Agency	U.S. Department of Defense	GHP-State	0
14466	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	684,760
16585	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,255,412
16588	US Embassy Guatemala	Other USG Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	55,092
16727	Management	NGO	U.S. Agency for	GHP-State,	1,853,508



	Sciences for		International	GHP-USAID	
	Health		Development		
17269	COMISCA	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,666
17270	UVG - UNIVERSIDAD DE VALLE DE GUATEMALA	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,971,937
17310	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	367,328
17407	TBD	TBD	Redacted	Redacted	Redacted
17433	LINKAGES	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	2,283,457
17894	TBD	TBD	Redacted	Redacted	Redacted
17895	TBD	TBD	Redacted	Redacted	Redacted
18349	TBD	TBD	Redacted	Redacted	Redacted
18371	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	565,750



Implementing Mechanism(s)

Implementing Mechanism Details

3		
Mechanism ID: 13082	Mechanism Name: Combination Prevention	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Services International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
El Salvador	687,002
Guatemala	1,311,673
Nicaragua	0
Panama	391,200

Total All Funding Sources 2,389,875	:	
Applied Pipeline Amount:	0	
Total All Funding Sources		
2,389,875		
Managing Country	Funding Source	Funding Amount
Guatemala	GHP-State	932,051
Guatemala	GHP-USAID	1,457,824

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	476,748
Focus Area:	Training of health workers and community outreach
	workers
Focus Area:	Implementation of core HIV prevention interventions



Docus Area: Cooppa Docus Area: Cooppa Docus Area: Mo	er MSM/TG that are consistent with the current EPFAR technical guidance collection and use of strategic information conducting epidemiologic, social science, and perational research among MSM/TG and their sex cartners conitoring and evaluation of MSM/TG programs 58,916	
ocus Area: Co op op pa ocus Area: Mo	ollection and use of strategic information onducting epidemiologic, social science, and perational research among MSM/TG and their sex artners onitoring and evaluation of MSM/TG programs	
ocus Area: Co op pa ocus Area: Mo	onducting epidemiologic, social science, and perational research among MSM/TG and their sex artners onitoring and evaluation of MSM/TG programs	
op pa pa pacus Area: Mo	perational research among MSM/TG and their sex partners onitoring and evaluation of MSM/TG programs	
D 1 (FOW	58,916	
ey Populations: FSW 15		
for	nplementation of core HIV prevention interventions or SWs consistent with PEPFAR guidance on exual prevention	
	raining of health workers and community outreach orkers	
	ollection and use of strategic information on SWs and clients	
ор	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients	
ocus Area: Mo	onitoring and evaluation of SW programs	
ender: GBV 38	37,800	
ocus Area: GE	BV Prevention	
	ollection and Use of Gender-related Strategic formation	
ub Area:	nplementation	
ub Area:	apacity building	
ub Area: Mo	onitoring and Evaluation	
ub Area: Op	peration Research	
ender: Gender Equality 11	17,096	
	quity in HIV prevention, care, treatment and upport	
	ollection and Use of Gender-related Strategic formation	
ub Area:	nplementation	



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Budget Code Information

Budget Code Inform	ation			
Mechanism ID:	13082			
Mechanism Name:	Combination Prevention			
Prime Partner Name:	Population Services Intervices	ernational		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	341,693	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	2,048,182	0	

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
El Salvador	KP_PREV_DSD	Number of key populations reached with	6,521



		individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
El Salvador	KP_PREV_DSD	Total estimated number of key population in the catchment area	10,918
El Salvador	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,589
El Salvador	KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
El Salvador	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	932
El Salvador	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	8,518
El Salvador	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,400
El Salvador	HTC_TST_DSD	Number of individuals who received T&C	3,260



		services for HIV and received their test	
		results during the past 12 months	
El Salvador	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,794
El Salvador	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	466
El Salvador	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,260
El Salvador	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	3,260
El Salvador	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	151
El Salvador	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	18
El Salvador	HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	3,260
Guatemala	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	11,481
Guatemala	KP_PREV_DSD	Total estimated number of key population in the catchment area	24,666
Guatemala	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,481
Guatemala	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	24,666
Guatemala	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,741



		,	
Guatemala	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,741
Guatemala	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,741
Guatemala	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	5,741
Guatemala	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	291
Guatemala	HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	5,741
Panama	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,606
Panama	KP_PREV_DSD	Total estimated number of key population in the catchment area	13,144
Panama	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,540
Panama	KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	66
Panama	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	13,144
Panama	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test	2,804



		results during the past 12 months	
Panama	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,804
Panama	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,804
Panama	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,804
Panama	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	141
Panama	HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	2,804

Implementing Mechanism Details

Mechanism ID: 13445	Mechanism Name: Capacity+	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: IntraHealth International, Inc		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
El Salvador	413,190
Guatemala	3,118,971
Panama	1,536,363

Total All Funding Sources 5,068,524	s:	
Applied Pipeline Amount:	0	
Total All Funding Sources	and Applied Pipeline Amount:	
5,068,524		
Managing Country	Funding Source	Funding Amount
Guatemala	GHP-State	2,037,724
Guatemala	GHP-USAID	3,030,800



Human Resources for Health	264,320	
Motor Vehicles: Leased	47,200	
Key Populations: MSM and TG	387,040	
Focus Area:	Training of health workers and community outreach workers	
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance	
Focus Area:	Collection and use of strategic information	
Key Populations: FSW	103,840	
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention	
Focus Area:	Training of health workers and community outreach workers	
Focus Area:	Collection and use of strategic information on SWs and clients	
Gender: Gender Equality	141,600	
Focus Area:	Changing harmful gender norms and promoting positive gender norms	
Sub Area:	Collection and Use of Gender-related Strategic Information	
Sub Area:	Implementation	
Sub Area:	Capacity building	
Sub Area:	Monitoring and Evaluation	
Focus Area:	Equity in HIV prevention, care, treatment and support	
Sub Area:	Collection and Use of Gender-related Strategic Information	
Sub Area:	Implementation	
Sub Area:	Capacity building	
Sub Area:	Monitoring and Evaluation	



Gender: GBV	186,000	
Focus Area:	GBV Prevention	
Sub Area:	Collection and Use of Gender-related Strategic Information	
Sub Area:	Implementation	
Sub Area:	Capacity building	
Sub Area:	Monitoring and Evaluation	

Budget Code Information

Budget Code Information			
Mechanism ID:	Mechanism ID: 13445		
Mechanism Name:	: Capacity+		
Prime Partner Name:	IntraHealth Internationa	I, Inc	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	2,864,351	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	65,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,139,173	0

Implementing Mechanism Indicator Information



OU	Indicator Number	Label	2017
Guatemala	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	10,174
Guatemala	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	5,817
Guatemala	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	4,357
Guatemala	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	10,174
Guatemala	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	10,174
Guatemala	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	410
Guatemala	TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	0
Guatemala	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	410
Guatemala	TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	0
Guatemala	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	0
Guatemala	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	410
Panama	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	6,582
Panama	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	4,190
Panama	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	2,392
Panama	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	6,582
Panama	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	6,582
Panama	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	193
Panama	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	193
Panama	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	193

Mechanism ID: 14401	Mechanism Name: US Department of Defense



Funding Agency: DOD	Procurement Type: USG Core	
Prime Partner Name: U.S. Department of Defense Naval Health Research Center		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
Guatemala	0
Honduras	0
Nicaragua	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 101,55		
Total All Funding Sources and Applied Pipeline Amount: 101,550		
Managing Country Funding Source		Funding Amount
Guatemala	GHP-State	0

(No data provided.)

Budget Code Information

Mechanism ID:			
Mechanism Name:	US Department of Defense		
Prime Partner Name:	U.S. Department of Defense Naval Health Research Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0



(No data provided.)

Implementing Mechanism Details

implementing incondition bottom		
Mechanism ID: 14466	Mechanism Name: PrevenSida	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: University Research Corporation, LLC		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
Nicaragua	684,760

Total All Funding Sources: 684,760		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
Managing Country Funding Source		Funding Amount
Nicaragua	GHP-State	267,056
Nicaragua	GHP-USAID	417,704

Cross-Cutting Budget Attribution(s)

<u></u>	-(-)
Human Resources for Health	14,000
Key Populations: MSM and TG	176,478
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information



Focus Area:	Conducting epidemiologic, social science, and
	operational research among MSM/TG and their sex
	partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other
	commodities essential to core HIV services for
	MSM/TG
Gender: GBV	98,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	45,000
Focus Area:	Changing harmful gender norms and promoting
	positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that
	increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Capacity building
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and
	support
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
	1



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Budget Code Information				
Mechanism ID:	14466			
Mechanism Name:	PrevenSida			
Prime Partner Name:	University Research Co	rporation, LLC		
Strategic Area	Budget Code Planned Amount On Hold Amount			
Care	НВНС	173,115	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	13,431	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	57,754	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	



Treatment	HTXS	440,460	0
-----------	------	---------	---

(No data provided.)

implementing mechanism betails			
Mechanism ID: 16585	Mechanism Name: Capacity Building in HIV Co-infection Activities to Address the Continuum of Prevention, Care and Treatment in Central America, CoAg # GH001100		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: University Research Corporation, LLC			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

Benefiting Country	Benefiting Country Planned Amount
El Salvador	279,157
Guatemala	308,377
Honduras	212,376
Nicaragua	156,213
Panama	299,289

Total All Funding Sources:		
1,255,412		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
1,255,412		
Managing Country	Funding Source	Funding Amount
Guatemala	GHP-State	1,255,412



Human Resources for Health	356,488

Budget Code Information

Budget Code Information				
	16585			
Mechanism ID:	Capacity Building in HIV Co-infection Activities to Address the			
Mechanism Name:	Mechanism Name: Continuum of Prevention, Care and Treatment in Central America, CoAg			
Prime Partner Name:	# GH001100			
	University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	608,547	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	646,865	0	

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
El Salvador	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	320
El Salvador	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	260
El Salvador	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	60
El Salvador	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	320
El Salvador	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	320
El Salvador	HTC_TST_DSD	Test Result by Aggregated Age and Sex:	13



		Positive 15+ Male	
El Salvador	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3
El Salvador	TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	17
El Salvador	TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	20
El Salvador	TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
El Salvador	TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
El Salvador	TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2
El Salvador	TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4
El Salvador	TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
El Salvador	TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1



El Salvador	TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	115
El Salvador	TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	85
El Salvador	TB_SCREENDX_TA	Screen Results: Screened Positive for TB	4
El Salvador	TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2
El Salvador	TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	2
El Salvador	TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2
El Salvador	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
El Salvador	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1
El Salvador	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	3
El Salvador	TB_SCREEN_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	200
Guatemala	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	
Guatemala	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	520
Guatemala	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	120
Guatemala	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	640
Guatemala	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	640
Guatemala	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	26



			1
Guatemala	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	6
Guatemala	TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	468
Guatemala	TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	566
Guatemala	TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
Guatemala	TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and	
Guatemala	TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	141
Guatemala TB ART TA		The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	9
Guatemala	TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	25
Guatemala	TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
Guatemala	TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new	3



and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Male 660 Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Female 285 Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Female 285 Guatemala TB_SCREENDX_TA Screened Positive for TB 19 [Sub-Disagg of Screen Results] Specimen Sent: Specimen Sent: Specimen Sent: Specimen Sent: Specimen Sent: Specimen Sent: Diagnostic Test: Smear Only Guatemala TB_SCREENDX_TA Sub-disagg of Specimen Sent! Diagnostic Test: Specimen Sent! Diagnostic Test: Specimen Sent! Diagnostic Test: Other (Not Xpert) Guatemala TB_SCREENDX_TA Specimen Sent! Diagnostic Test: Other (Not Xpert) HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that perform this		1		
Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Male 660 Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Female 285 Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Female 285 Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Female 285 Guatemala TB_SCREENDX_TA Screened Positive for TB 19 [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 201 Guatemala TB_SCREENDX_TA Sent: Specimen Sent! Diagnostic Test: Smear Only 201 Guatemala TB_SCREENDX_TA Screened Positive for TB 19 [Sub-Disagg of Screen Results] Specimen Sent: Specimen Sent: Operation of the properties of t			and relapse TB cases with documented	
Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Male 660 Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Female 285 Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Female 285 Guatemala TB_SCREENDX_TA Screen Results: Screened Positive for TB 19 Guatemala TB_SCREENDX_TA Screen Results: Screened Positive for TB 19 Guatemala TB_SCREENDX_TA Screen Results: Screened Positive for TB 19 Guatemala TB_SCREENDX_TA Screen Results: Screened Positive for TB 19 Guatemala TB_SCREENDX_TA Screen Results: Screened Positive for TB 19 Guatemala TB_SCREENDX_TA Screen Results: Screened Positive for TB 11 Guatemala TB_SCREENDX_TA Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 3 Guatemala LAB_PT_TA HIV serologic/diagnostic testing: Number of Iaboratories that achieve acceptable successful passing criteria in this PT program 3 Guatemala LAB_PT_TA HIV serologic/diagnostic testing: Number of Iaboratories that perform this testing 6 Guatemala <		HIV-positive status who are on ART during		
Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Female 285 Guatemala TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Female 19 [Sub-Disagg of Screen Results] Specimen Sent: Spec		TB treatment during the reporting period)		
Guatemala TB_SCREENDX_TA Screen Results: Screened Positive for TB [Sub-Disagg of Screen Results] Specimen Sent: Specimen Sent: Specimen Sent: Specimen Sent: Specimen Sent: Diagnostic diagnosis of active TB [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) Diagnost	Guatemala	TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	660
Guatemala TB_SCREENDX_TA Sent: Specimen sent for bacteriologic diagnosis of active TB Guatemala TB_SCREENDX_TA Sent: Specimen Sent! Diagnostic Test: Smear Only Guatemala TB_SCREENDX_TA Sent: Specimen Sent! Diagnostic Test: Smear Only [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program Guatemala LAB_PT_TA HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program Guatemala LAB_PT_TA HIV serologic/diagnostic testing: Number of laboratories that perform this testing Guatemala TB_SCREEN_TA The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period Number of individuals who received T&C services for HIV and received their test results during the past 12 months Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	Guatemala	TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	285
Guatemala TB_SCREENDX_TA Sent: Specimen sent for bacteriologic diagnosis of active TB Guatemala TB_SCREENDX_TA Guatemala LAB_PT_TA HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that perform this testing Guatemala LAB_PT_TA HIV serologic/diagnostic testing: Number of laboratories that perform this testing The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period Number of individuals who received T&C services for HIV and received their test results during the past 12 months Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	Guatemala	TB_SCREENDX_TA	Screen Results: Screened Positive for TB	19
Guatemala IB_SCREENDX_TA Test: Smear Only [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay Guatemala TB_SCREENDX_TA Guatemala TB_SCREENDX_TA [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that perform this testing The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period Number of individuals who received T&C services for HIV and received their test results during the past 12 months Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	Guatemala	TB_SCREENDX_TA	Sent: Specimen sent for bacteriologic	11
Guatemala TB_SCREENDX_TA Test: Xpert MTB/RIF assay [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that perform this testing The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period Panama HTC_TST_DSD Panama Number of individuals who received T&C services for HIV and received their test results during the past 12 months Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	Guatemala	TB_SCREENDX_TA		11
Guatemala TB_SCREENDX_TA Test: Other (Not Xpert) HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that perform this testing The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period Number of individuals who received T&C services for HIV and received their test results during the past 12 months Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	Guatemala	TB_SCREENDX_TA		3
Guatemala LAB_PT_TA laboratories that achieve acceptable successful passing criteria in this PT program HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program Guatemala LAB_PT_TA HIV serologic/diagnostic testing: Number of laboratories that perform this testing The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period Number of individuals who received T&C services for HIV and received their test results during the past 12 months Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	Guatemala	TB_SCREENDX_TA		8
Guatemala LAB_PT_TA laboratories that participate in this PT program HIV serologic/diagnostic testing: Number of laboratories that perform this testing The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period Panama HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	Guatemala	LAB_PT_TA	laboratories that achieve acceptable successful passing criteria in this PT	3
Guatemala LAB_PT_TA laboratories that perform this testing The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period Panama HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male Panama Aggregated Age/sex - WSE WITH HQ PERMISSION ONLY: 15+ Male	Guatemala	LAB_PT_TA	laboratories that participate in this PT	
Guatemala TB_SCREEN_TA for TB symptoms at the last clinical visit to an HIV care facility during the reporting period Number of individuals who received T&C services for HIV and received their test results during the past 12 months Panama HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	Guatemala	LAB_PT_TA		
Panama HTC_TST_DSD services for HIV and received their test results during the past 12 months Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 480	Guatemala	TB_SCREEN_TA	for TB symptoms at the last clinical visit to an HIV care facility during the reporting	
Panama HTC_TST_DSD PERMISSION ONLY: 15+ Male	Panama	HTC_TST_DSD	services for HIV and received their test 60	
Panama HTC_TST_DSD Aggregated Age/sex - USE WITH HQ 120	Panama	HTC_TST_DSD	480	
	Panama	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	120



		PERMISSION ONLY: 15+ Female	
Panama	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	600
Panama	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	600
Panama	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	24
Panama	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	6
Panama	TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	110
Panama	TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	134
Panama	TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	78
Panama	TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	32
Panama	TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	
Panama	TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	10
Panama	TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
Panama	TB_ART_TA	Aggregated Age/Sex: Female 15+	2



	T			
		(Numerator: The number of registered new and relapse TB cases with documented		
		HIV-positive status who are on ART during		
		TB treatment during the reporting period)		
Panama	TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	310	
Panama	TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	220	
Panama	TB_SCREENDX_TA	Screen Results: Screened Positive for TB	10	
Panama	TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	6	
Panama	TB_SCREENDX_TA [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only		6	
Panama	TB_SCREENDX_TA	DX_TA [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay		
Panama	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		
Panama	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	of 1	
Panama	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	3	
Panama	TB_SCREEN_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		

Mechanism ID: 16588	Mechanism Name: Capacity building in strategic information and laboratory functions to address the continuum of prevention, care and treatment in Central America
Funding Agency: HHS/CDC	Procurement Type: Inter-Agency Agreement
Prime Partner Name: US Embassy Guatemala	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
El Salvador	7,500
Guatemala	28,534
Honduras	7,326
Nicaragua	4,035
Panama	7,697

Total All Funding Sources: 55,092		
Applied Pipeline Amount:		
Total All Funding Sources	and Applied Pipeline Amount:	55,092
Managing Country Funding Source		Funding Amount
Guatemala	GHP-State	55,092

(No data provided.)

Budget Code Information

Daaget Code Inform	ation		
	16588		
Mechanism ID:	Capacity building in strategic information and laboratory functions to		
Mechanism Name:	address the continuum of prevention, care and treatment in Central		
Prime Partner Name:	: America		
	US Embassy Guatemala		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and	HVSI	55,092	0
Systems	11001	33,032	O

(No data provided.)

implementing mechanism betans			
Mechanism ID: 16727	Mechanism Name: Bridge USAID Program for Strengthening the Central American Response		
	,		
	to HIV -PASCA-		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Management Sciences for Health			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

Benefiting Country	Benefiting Country Planned Amount
El Salvador	555,208
Guatemala	939,300
Nicaragua	82,000
Panama	277,000

Total All Funding Sources: 1,853,508				
Applied Pipeline Amount: 0				
Total All Funding Sources a				
1,853,508				
Managing Country	Funding Source	Funding Amount		
Guatemala	GHP-State	735,678		
Guatemala	GHP-USAID	1,117,830		



Key Populations: MSM and TG	120,000
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	30,000
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	165,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	25,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Leased	10,000

Budget Code Information

Mechanism ID: Mechanism Name:	Bridge USAID Program for Strengthening the Central American Response to HIV -PASCA-		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	4,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	275,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	962,208	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	18,300	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	592,800	0
------------	------	---------	---

(No data provided.)

Implementing Mechanism Details			
	Mechanism Name: Strengthening HIV		
	Surveillance, Linkages to HIV services, and HIV		
Mechanism ID: 17269	Diagnostic Capacity to address the continuum		
	of prevention, care and treatment in Central		
	America, CoAg#GH001602		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: COMISCA			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

Benefiting Country	Benefiting Country Planned Amount
El Salvador	114,548
Guatemala	51,214
Honduras	31,856
Nicaragua	41,795
Panama	111,253

Total All Funding Sources: 350,666		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
Managing Country	Funding Amount	
Guatemala	GHP-State	350,666



Human Resources for Health	252,431

Budget Code Information				
	17269			
Mechanism ID:	Strengthening HIV Surv	Strengthening HIV Surveillance, Linkages to HIV services, and HIV		
Mechanism Name:	Diagnostic Capacity to a	Diagnostic Capacity to address the continuum of prevention, care and		
Prime Partner Name:	treatment in Central Ame	erica, CoAg#GH001602		
	COMISCA			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	350,666	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	0	0	

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
El Salvador	LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1
El Salvador	LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1
El Salvador	LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1



		,	
El Salvador	LAB_PT_DSD	CD4: Number of laboratories that perform this testing	1
El Salvador	LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	1
El Salvador	LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
El Salvador	LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
El Salvador	LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
El Salvador	LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Guatemala	LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	3
Guatemala	LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	3
Guatemala	LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
Guatemala	LAB_PT_DSD	CD4: Number of laboratories that perform this testing	2
Guatemala	LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	2
Guatemala	LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
Guatemala	LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	2
Guatemala	LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	2



Guatemala	LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
Panama	LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1
Panama	LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1
Panama	LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Panama	LAB_PT_DSD	CD4: Number of laboratories that perform this testing	1
Panama	LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	1
Panama	LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Panama	LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
Panama	LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
Panama	LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1

Mechanism ID: 17270	Mechanism Name: Building capacity along the continuum of prevention, care and treatment for key populations in Central America, CoAg # GH001285
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UVG - UNIVERSIDAD DE VAL	LE DE GUATEMALA
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
El Salvador	252,731
Guatemala	857,900
Honduras	719,732
Nicaragua	681,599
Panama	459,971

Total All Funding Sources: 2,971,937		
Applied Pipeline Amount: 0		
Total All Funding Sources and A	Applied Pipeline Amount:	
2,971,937		
Managing Country	Funding Source	Funding Amount
Guatemala	GHP-State	2,971,937

Key Populations: FSW	101,832
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	2,023,812
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information



Mechanism ID: Mechanism Name:	Building capacity along the continuum of prevention, care and treatment for key populations in Central America, CoAg # GH001285					
Strategic Area	Budget Code	Budget Code Planned Amount On Hold Amount				
Governance and Systems	HLAB	190,700	C			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Prevention	HVCT	781,927	O			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Prevention	HVOP	1,586,379	O			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Treatment	HTXS	412,931	C			

OU	Indicator Number	Label	2017
El Salvador	KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,629
El Salvador	KP_PREV_TA	Total estimated number of key population in the catchment area	4,352
El Salvador	KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key	519



Г	T		
		populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
El Salvador	KP_PREV_TA	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,755
El Salvador	KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,502
El Salvador	KP_PREV_TA	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	608
El Salvador	KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	2,234
El Salvador	KP_PREV_TA	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	363
El Salvador	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,174
El Salvador	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,863



El Salvador	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	311
El Salvador	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,174
El Salvador	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,174
El Salvador	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	98
El Salvador	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	14
El Salvador	HTC_TST_TA	Service Delivery Point (Facility): VCT	2,117
El Salvador	HTC_TST_TA	Service Delivery Point (Facility): Index testing	57
El Salvador	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
El Salvador	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	4
El Salvador	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	4
Guatemala	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,506
Guatemala	KP_PREV_DSD	Total estimated number of key population in the catchment area	14,034
Guatemala	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,285
Guatemala	KP_PREV_DSD	By key population type: Transgender who	221



		are NOT sex workers (Numerator: Number	
		of key populations reached with individual	
		and/or small group level HIV preventive	
		interventions that are based on evidence	
		and/or meet the minimum standards	
		required)	
		By key population type: Men who have sex	
	1/D DDE1/ DOD	with men who are NOT sex workers	40
Guatemala	KP_PREV_DSD	(Denominator: Total estimated number of	13,579
		key population in the catchment area)	
		By key population type: Transgender who	
		are NOT sex workers (Denominator: Total	
Guatemala	KP_PREV_DSD	estimated number of key population in the	455
		catchment area)	
		Number of individuals who received T&C	
Guatemala	HTC_TST_DSD	services for HIV and received their test	5.006
Guatemala	1110_131_030	results during the past 12 months	5,096
Guatemala	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	5,096
		PERMISSION ONLY: 15+ Male	
Guatemala	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	0
		PERMISSION ONLY: 15+ Female	
Guatemala	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,096
Guatemala	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	5,096
	LITO TOT DOD	Test Result by Aggregated Age and Sex:	050
Guatemala	HTC_TST_DSD	Positive 15+ Male	258
		Test Result by Aggregated Age and Sex:	
Guatemala	HTC_TST_DSD	Positive 15+ Female	0
Guatemala	HTC_TST_DSD	Service Delivery Point (Facility): VCT	4,965
2		Service Delivery Point (Facility): Index	-,000
Guatemala	HTC_TST_DSD	testing	131
		_	
Guatemala	LAB_PT_DSD	HIV serologic/diagnostic testing: Number of	6
		laboratories that perform this testing	
		HIV serologic/diagnostic testing: Number of	
Guatemala	LAB_PT_DSD	laboratories that participate in this PT	6
		program	



	1	,	
Guatemala	LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
Guatemala	LAB_PT_DSD	CD4: Number of laboratories that perform this testing	3
Guatemala	LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	3
Guatemala	LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
Panama	KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,845
Panama	KP_PREV_TA	Total estimated number of key population in the catchment area	7,724
Panama	KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,786
Panama	KP_PREV_TA	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	59
Panama	KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of	7,468



		key population in the catchment area)	
Panama	KP_PREV_TA	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	256
Panama	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,302
Panama	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,302
Panama	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0
Panama	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,302
Panama	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,302
Panama	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	115
Panama	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	0
Panama	HTC_TST_TA	Service Delivery Point (Facility): VCT	2,243
Panama	HTC_TST_TA	Service Delivery Point (Facility): Index testing	59
Panama	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	37
Panama	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	18
Panama	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	19
Panama	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	37
Panama	LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Panama	LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	1
Panama	LAB_PT_TA	CD4: Number of laboratories that perform	1



		this testing	
Panama	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
Panama	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	5
Panama	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	5

Mechanism ID: 17310	Mechanism Name: Peer-to-peer capacity building of Ministries of Health in HIV surveillance in Central America, CoAg # GH001508
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
El Salvador	34,580
Guatemala	34,580
Honduras	97,573
Nicaragua	101,150
Panama	99,445

Total All Funding Sources:		
367,328		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 367,328		



Managing Country	Funding Source	Funding Amount
Guatemala	GHP-State	367,328

Cross-Cutting Budget Attribution	11(3)
Human Resources for Health	36,733
Key Populations: FSW	36,733
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	73,466
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information

Budget Code Information

Budget Code information			
Mechanism ID:	Peer-to-peer capacity building of Ministries of Health in HIV surveillance in Central America. CoAg # GH001508		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	367,328	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Custom Page 248 of 258 FACTS Info v3.8.21.7



Mechanism ID: 17407	TBD: Yes
REDACTED	

Mechanism ID: 17433	Mechanism Name: Linkages	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: LINKAGES		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
Honduras	2,283,457

Total All Funding Sources 2,283,457	s:	
Applied Pipeline Amount: 100,540 Total All Funding Sources and Applied Pipeline Amount:		
2,383,997		
Managing Country	Funding Source	Funding Amount
Honduras	GHP-State	890,548
Honduras	GHP-USAID	1,392,909

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	475,608
Focus Area:	Training of health workers and community outreach
	workers
Focus Area: Implementation of core HIV prevention in	
	for MSM/TG that are consistent with the current
	PEPFAR technical guidance



Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	158,536
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	383,600
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	116,816
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Budget Code Information			
Mechanism ID: Mechanism Name: Prime Partner Name:	Linkages		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	358,210	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	410,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	182,936	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	945,091	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	387,220	0

(No data provided.)



Mechanism ID: 17894	TBD: Yes
REDACTED	

Mechanism ID: 17895	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18349	TBD: Yes	
REDACTED		

Mechanism ID: 18371	Mechanism Name: Global Health Supply Chain	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Global Health Supply Chain Program		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
G2G: No	Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
El Salvador	173,750
Guatemala	293,000
Panama	99,000

Total All Funding Sources:		
565,750		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 565,750		
Managing Country	Funding Source	Funding Amount



Guatemala	GHP-State	220,643
Guatemala	GHP-USAID	345,107

Grood Gatting Badgot Attribution(c)	
Motor Vehicles: Leased	23,785
Key Populations: MSM and TG	55,343
Focus Area:	Collection and use of strategic information
Key Populations: FSW	27,672
Focus Area:	Collection and use of strategic information on SWs and clients

Budget Code Information

Mechanism ID:	8371							
Mechanism Name:	Global Health Supply C	hain						
Prime Partner Name:	Global Health Supply C	hain Program						
Strategic Area	Budget Code	Budget Code Planned Amount On Hold Amount						
Care	НВНС	5,000	0					
Strategic Area	Budget Code	Planned Amount	On Hold Amount					
Treatment	HTXS	560,750	0					

Implementing Mechanism Indicator Information

(No data provided.)

Agency Information - Costs of Doing Business

U.S. Agency for International Development

Agency Cost	GAP	GHP-State	GHP-USAID	Applied	Total	Total All
-------------	-----	-----------	-----------	---------	-------	-----------

Custom Page 253 of 258 FACTS Info v3.8.21.7



of Doing Business				Pipeline		Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		26,641	49,477	0	76,118	76,118
ICASS		28,568	53,055	0	81,623	81,623
Management Meetings/Profes sional Development		0		22,839	0	22,839
Non-ICASS Administrative Costs		52,786	97,935	4,555	150,721	155,276
Staff Program Travel		7,541	14,005	112,390	21,546	133,936
USG Renovation		1,750	3,250	5,000	5,000	10,000
USG Staff Salaries and Benefits - Internationally Recruited		21,648	40,202	0	61,850	61,850
USG Staff Salaries and Benefits - Locally Recruited		183,294	340,402	105,291	523,696	628,987
Total	0	322,228	598,326	250,075	920,554	1,170,629



U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		0		3,000	0	3,000
Management Meetings/Profes sional Development		0		20,000	0	20,000
Staff Program Travel		0		26,500	0	26,500
USG Staff Salaries and Benefits - Locally Recruited		0		96,000	0	96,000
Total	0	0	0	145,500	0	145,500

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention



Total	622,500	1,016,176	0	0	1,638,676	1,638,676
Recruited						
Locally						
Benefits -	266,593	278,981		0	545,574	545,574
Salaries and						
USG Staff						
Recruited						
Internationally						
Benefits -	355,907			0	355,907	355,907
Salaries and						
USG Staff						
Travel		157,131		0	157,131	157,131
Staff Program				_		
Costs						•
Administrative		287,163		0	287,163	287,163
Non-ICASS						
Development						
sional		19,500		0	19,500	19,500
Management Meetings/Profes						
ICASS		138,911		0	138,911	138,911
Services		100.011			100.011	400.044
Computers/IT		35,000		0	35,000	35,000
Cost Sharing		99,490		0	99,490	99,490
Capital Security						

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied
-------------------------------------	-----	-----------	-----------	---------------------	-------	---



						Pipeline Amount
Capital Security Cost Sharing		20,000		0	20,000	20,000
ICASS		5,000		0	5,000	5,000
Management Meetings/Profes sional Development		8,000		0	8,000	8,000
Non-ICASS Administrative Costs		40,000		0	40,000	40,000
Staff Program Travel		20,000		0	20,000	20,000
USG Staff Salaries and Benefits - Internationally Recruited		135,216		0	135,216	135,216
USG Staff Salaries and Benefits - Locally Recruited		30,400		0	30,400	30,400
Total	0	258,616	0	0	258,616	258,616

U.S. Peace Corps



						Pipeline Amount
Computers/IT Services		0		1,000	0	1,000
Management Meetings/Profes sional Development		0		3,000	0	3,000
Non-ICASS Administrative Costs		0		1,000	0	1,000
Staff Program Travel		0		5,000	0	5,000
USG Staff Salaries and Benefits - Locally Recruited		0		33,160	0	33,160
Total	0	0	0	43,160	0	43,160